<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2104221967
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ATECTURA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MOMETASONE FUROATE,(indacaterol (as acetate
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80,150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Inhalation powder, hard capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        108.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Siegfried Barbera S.L" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Siegfried Barbera S.L
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Novartis Europharm Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03AK
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Atectura Breezhaler<em> </em>is and how it works</p><p>Atectura Breezhaler<em> </em>contains two active substances called indacaterol and mometasone furoate.</p><p>&nbsp;</p><p>Indacaterol belongs to a group of medicines called bronchodilators. It relaxes the muscles of the small airways in the lungs. This helps to open the airways and makes it easier for air to get in and out of the lungs. When it is taken regularly, it helps the small airways to remain open.</p><p>&nbsp;</p><p>Mometasone furoate belongs to a group of medicines called corticosteroids (or steroids). Corticosteroids reduce the swelling and irritation (inflammation) in the small airways in the lungs and so gradually ease breathing problems. Corticosteroids also help to prevent attacks of asthma.</p><p>&nbsp;</p><p>What Atectura Breezhaler is used for</p><p>Atectura Breezhaler is used regularly as treatment for asthma in adults and adolescents (12&nbsp;years of age and older).</p><p>&nbsp;</p><p>Asthma is a serious, long‑term lung disease where the muscles surrounding the smaller airways become tight (bronchoconstriction) and inflamed. Symptoms come and go and include shortness of breath, wheezing, chest tightness and cough.</p><p>&nbsp;</p><p>You should use Atectura Breezhaler every day and not only when you have breathing problems or other symptoms of asthma. This will ensure that it controls your asthma properly. Do not use this medicine to relieve a sudden attack of breathlessness or wheezing.</p><p>&nbsp;</p><p>If you have any questions about how Atectura Breezhaler works or why this medicine has been prescribed for you, ask your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all the doctor&rsquo;s instructions carefully.</p><p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Do not use Atectura Breezhaler</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to indacaterol, mometasone furoate or any of the other ingredients of this medicine (listed in section&nbsp;6). If you think you may be allergic, ask your doctor for advice.</p><p>&nbsp;</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take special care with Atectura Breezhaler</p><p>Talk to your doctor, pharmacist or nurse before using Atectura Breezhaler if any of the following applies to you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart problems, including an irregular or fast heartbeat.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have thyroid gland problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever been told you have diabetes or high blood sugar.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from seizures or fits.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a low level of potassium in your blood.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have tuberculosis (TB) of the lung, or any long‑standing or untreated infections.</p><p>&nbsp;</p><p><strong>D</strong><strong>uring treatment with Atectura Breezhaler</strong></p><p><strong>Stop using this medicine and get medical help immediately</strong> if you have any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tightness of the chest, coughing, wheezing or breathlessness immediately after using Atectura Breezhaler (signs the medicine is unexpectedly tightening the airways, known as paradoxical bronchospasm).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing or swallowing, swelling of the tongue, lips or face, skin rash, itching and hives (signs of allergic reaction).</p><p>&nbsp;</p><p>Children and adolescents</p><p>Do not give this medicine to children below 12&nbsp;years of age because it has not been studied in this age group.</p><p>&nbsp;</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Using other medicines and Atectura Breezhaler</p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. In particular, tell your doctor or pharmacist if you are using:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that decrease the level of potassium in your blood. These include diuretics (which increase urine production and can be used to treat high blood pressure, e.g. hydrochlorothiazide), other bronchodilators such as methylxanthines used for breathing problems (e.g. theophylline) or corticosteroids (e.g. prednisolone).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tricyclic antidepressants or monoamine oxidase inhibitors (medicines used in the treatment of depression).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any medicines that may be similar to Atectura Breezhaler (contain similar active substances); using them together may increase the risk of possible side effects.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines called beta blockers used to treat high blood pressure or other heart problems (e.g. propranolol) or to treat glaucoma (e.g. timolol).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole or itraconazole (medicines used to treat fungal infections)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir, nelfinavir or cobicistat (medicines used to treat HIV infection).</p><p>&nbsp;</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnancy and breast‑feeding</p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will discuss with you whether you can use Atectura Breezhaler.</p><p>&nbsp;</p><p><strong>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Driving and using machines</strong></p><p>It is unlikely that this medicine will affect your ability to drive and use machines.</p><p>&nbsp;</p><p><strong>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Important information about some of the ingredients of Atectura Breezhaler</strong></p><p><strong>Atectura Breezhaler contains lactose</strong></p><p>This medicine contains about 25&nbsp;mg of lactose per capsule. If you have been told by your doctor that you have an intolerance to some sugars, speak with your doctor before taking this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>How much Atectura Breezhaler<em> </em>to inhale</p><p>There are three different strengths of Atectura Breezhaler capsules. Your doctor will decide which is best for you.</p><p>&nbsp;</p><p>The usual dose is to inhale the content of one capsule each day. You only need to use the medicine once a day. Do not use more than your doctor tells you to use.</p><p>&nbsp;</p><p>You should use Atectura Breezhaler every day, even when your asthma is not troubling you.</p><p>&nbsp;</p><p>When to inhale Atectura Breezhaler</p><p>Inhale Atectura Breezhaler at the same time each day. This will help control your symptoms throughout the day and night. It will also help you to remember to use it.</p><p>&nbsp;</p><p>How to inhale Atectura Breezhaler</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atectura Breezhaler is for inhalation use.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In this pack, you will find an inhaler and capsules that contain the medicine. The inhaler enables you to inhale the medicine in the capsule. Only use the capsules with the inhaler provided in this pack. The capsules should remain in the blister until you need to use them.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peel the backing away from the blister to open it, <strong>do not push the capsule through the foil</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When you start a new pack, use the new inhaler supplied in this new pack.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dispose of the inhaler in each pack after all capsules in that pack have been used.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not swallow the capsules.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Please read the instructions for use on the other side of this leaflet for more information on how to use the inhaler.</strong></p><p>&nbsp;</p><p><strong>If your symptoms do not improve</strong></p><p>If your asthma is not getting better or if it gets worse after you have started using Atectura Breezhaler, talk to your doctor.</p><p>&nbsp;</p><p>If you use more Atectura Breezhaler than you should</p><p>If you accidently inhale too much of this medicine, contact your doctor or hospital for advice immediately. You may need medical attention.</p><p>&nbsp;</p><p>If you forget to use Atectura Breezhaler</p><p>If you forget to inhale a dose at the usual time, inhale one as soon as possible on that day. Then inhale the next dose at the usual time on the next day. Do not inhale two doses on the same day.</p><p>&nbsp;</p><p>If you stop using Atectura Breezhaler</p><p>Do not stop using Atectura Breezhaler unless your doctor tells you to. Your asthma symptoms may come back if you stop using it.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Some side effects could be serious</strong></p><p>Stop using Atectura Breezhaler and get medical help immediately if you have any of the following:</p><p>&nbsp;</p><p><strong>Common: </strong>may affect up to 1 in every 10&nbsp;people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing or swallowing, swelling of the tongue, lips, or face, skin rash, itching and hives (signs of allergic reaction).</p><p>&nbsp;</p><p><strong>Uncommon:</strong> may affect up to 1 in every 100&nbsp;people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling mainly of the tongue, lips, face or throat (possible signs of angioedema).</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Other side effects include the following listed below. If these side effects become severe, please tell your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p><strong>Very common:</strong> may affect more than 1 in 10&nbsp;people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; runny nose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden difficulty breathing and feeling of tightness in chest with wheezing or coughing</p><p>&nbsp;</p><p><strong>Common: </strong>may affect up to 1 in every 10&nbsp;people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; voice alteration (hoarseness)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blocked nose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sneezing, cough</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in muscles, bones or joints (signs of musculoskeletal pain)</p><p>&nbsp;</p><p><strong>Uncommon:</strong> may affect up to 1 in every 100&nbsp;people</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart beat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral thrush (sign of candidiasis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of sugar in the blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasm</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin itching</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clouding of the lens of your eyes (signs of cataract)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and blister after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicinal product does not require any special temperature storage conditions.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store the capsules in the original blister in order to protect from light and moisture, and do not remove until immediately before use.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are indacaterol (as acetate) and mometasone furoate.</p><p>&nbsp;</p><p><u>Atectura Breezhaler 125&nbsp;micrograms/62.5&nbsp;micrograms</u></p><p>Each capsule contains 173&nbsp;micrograms of indacaterol acetate (equivalent to 150&nbsp;micrograms of indacaterol) and 80&nbsp;micrograms of mometasone furoate. The delivered dose (the dose that leaves the mouthpiece of the inhaler) is equivalent to 125&nbsp;micrograms of indacaterol and 62.5&nbsp;micrograms of mometasone furoate.</p><p>&nbsp;</p><p><u>Atectura Breezhaler 125&nbsp;micrograms/127.5&nbsp;micrograms</u></p><p>Each capsule contains 173&nbsp;micrograms of indacaterol acetate (equivalent to 150&nbsp;micrograms of indacaterol) and 160&nbsp;micrograms of mometasone furoate. The delivered dose (the dose that leaves the mouthpiece of the inhaler) is equivalent to 125&nbsp;micrograms of indacaterol and 127.5&nbsp;micrograms of mometasone furoate.</p><p>&nbsp;</p><p><u>Atectura Breezhaler 125&nbsp;micrograms/260&nbsp;micrograms</u></p><p>Each capsule contains 173&nbsp;micrograms of indacaterol acetate (equivalent to 150&nbsp;micrograms of indacaterol) and 320&nbsp;micrograms of mometasone furoate. The delivered dose (the dose that leaves the mouthpiece of the inhaler) is equivalent to 125&nbsp;micrograms of indacaterol and 260&nbsp;micrograms of mometasone furoate.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredient is lactose monohydrate (see &ldquo;Atectura Breezhaler contains lactose&rdquo; in section&nbsp;2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                In this pack, you will find an inhaler together with capsules in blisters. The capsules are transparent and contain a white powder.
-	Atectura Breezhaler 125 micrograms/62.5 micrograms capsules have a blue product code “IM150 80” printed above one blue bar on the body with a logo printed in blue and surrounded by two blue bars on the cap.
-	Atectura Breezhaler 125 micrograms/127.5 micrograms capsules have a grey product code “IM150 160” printed on the body with a logo printed in grey on the cap.
-	Atectura Breezhaler 125 micrograms/260 micrograms capsules have a black product code “IM150 320” printed above two black bars on the body with a logo printed in black and surrounded by two black bars on the cap.

The following pack sizes are available:
Single pack containing 30 x 1 hard capsules together with 1 inhaler.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved by EMA in 06/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ما هو عقار أتكتورا بريزهيلير وكيف يعمل؟</p><p dir="RTL">يحتوي عقار أتكتورا بريزهيلير على مادتين فعَّالتين تُسميان إنداكاتيرول و موميتازون فيوروات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينتمي إنداكاتيرول إلى مجموعة من الأدوية تسمى موسعات الشُّعب الهوائية. يُرخي العقار عضلات المسالك الهوائية الصغيرة في الرئتين. يساعد ذلك على فتح المسالك الهوائية، الأمر الذي يُسَهِّل من دخول الهواء إلى الرئتين وخروجه منهما. عند تناوُله بصفة منتظمة، يُساعِد العقار على إبقاء المسالك الهوائية الصغيرة مفتوحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينتمي موميتازون فيوروات إلى مجموعة من الأدوية تسمى الكورتيكوستيرويدات (أو الستيرويدات). تحد الكورتيكوستيرويدات من تورُّم المسالك الهوائية الصغيرة بالرئتين وتهيُّجها (التهابها)، وهو ما يخفف مشاكل التَّنفس تدريجيًّا. تُساعد الكورتيكوستيرويدات أيضًا على الوقاية من نوبات الربو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ما هي دواعي استعمال عقار أتكتورا بريزهيلير</p><p dir="RTL">يُستخدم عقار أتكتورا بريزهيلير بانتظام لعلاج الربو في البالغين والمراهقين (الذين يبلغون من العمر 12 عامًا فأكثر)</p><p dir="RTL">&nbsp;</p><p dir="RTL">الربو هو مرض رئوي خطير وطويل الأمد تصبح فيه العضلات المحيطة بالمسالك الهوائية الأصغر حجمًا مشدودة (تضيُّق قصبي) وملتهبة. تظهر الأعراض ثم تختفي وتشمل ضيق النفس، أزيزًا بالصدر، ضيق الصدر وسعالًا.</p><p dir="RTL">يجب عليك استخدام عقار أتكتورا بريزهيلير كل يوم وألا يقتصر استخدامك له على الأوقات التي تُعاني فيها من مشاكل في التنفس أو غيرها من أعراض الربو. سيضمن ذلك تحكم العقار في الربو كما ينبغي. يُحظَر استخدام هذا الدَّواء لتخفيف نوبةٍ مفاجئةٍ من عُسْر التَّنَفُّس أو أزيز الصدر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة حول كيفية عمل عقار أتكتورا بريزهيلير أو لماذا تم وصف هذا الدواء لك، فاستشر طبيبك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">اتبع جميع تعليمات الطبيب بعناية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال عقار أتكتورا بريزهيلير</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه إنداكاتيرول، موميتازون فيوروات أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء (المدرجة في قسم: 6). إذا كنت تعتقد أنك قد تكون لديك حساسية، فاستشر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال عقار أتكتورا بريزهيلير </strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة) قبل استخدام عقار أتكتورا بريزهيلير في الحالات الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال كنت تُعاني من مشاكل قلبية، من ضمنها عدم انتظام ضربات القلب أو تسارعها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمشاكل في الغدة الدرقية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال أُخبِرت سابقًا بأنك تعاني من مرض السُّكَّري أو ارتفاع مستوى السُّكَّر بالدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نوبات صرع أو تشنجات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال انخفاض مستوى البوتاسيوم في دمك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل شديدة بالكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال كنت تعاني من السُّل الرئوي أو أي عدوى قائمة لفترة طويلة أو عدوى لم تُعالج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء العلاج بعقار أتكتورا بريزهيلير</strong></p><p dir="RTL"><strong>توقف عن استخدام هذا الدَّواء واطلب المساعدة الطبية فورًا</strong> إذا أُصِبت بأيٍّ من الآتي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق بالصدر، أو سعال، أو أزيز بالصدر أو عُسْر التَّنَفُّس فور استخدام عقار أتكتورا بريزهيلير (علامات تشير إلى تسبب الدَّواء في تضيُّق غير متوقع في المسالك الهوائية؛ وتُعرَف هذه الحالة بالتشنُّج القصبي التناقضي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التَّنفس أو البلع، أو تورم اللسان أو الشفتين أو الوجه، أو الطفح الجلدي، أو الحكة والشرى (أرتكاريا) (علامات تشير إلى الإصابة بتفاعل حساسية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال والمراهقون</p><p dir="RTL">لا تعطِ هذا الدَّواء للأطفال ممن تقل أعمارهم عن 12 عامًا؛ ذلك لأن هذا الدَّواء لم يخضع بعد للدراسة في هذه الفئة العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التداخلات الدوائية من أخذ هذا المستحضر مع أدوية أخرى أو أعشاب أو مكملات غذائية</p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيَّة أدوية أخرى. على وجه الخصوص، أخبر الطبيب أو الصيدلي الخاص بك إذا كنت تستخدم أيًّا مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية خافضة لمستوى البوتاسيوم في الدَّم. تشمل هذه الأدوية مُدِرات البول (التي تزيد من إنتاج البول والتي يُمكن استخدامها لعلاج ارتفاع ضغط الدَّم، على سبيل المثال: هيدروكلوروثيازيد)، مُوَسِّعات الشُّعب الهوائية الأخرى مثل الميثيلزانثينات التي تُستخدم لعلاج مشاكل التنفس (على سبيل المثال: ثيوفيلين) أو الكورتيكوستيرويدات (على سبيل المثال: بريدنيزولون).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب ثلاثية الحلقات أو مثبطات أوكسيديز أحادي الأمين (أدوية تُستخدم لعلاج الاكتئاب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أيَّة أدوية قد تكون مماثلة لعقار أتكتورا بريزهيلير (تحتوي على مواد فَعَّالة مماثلة)؛ فقد يزيد استخدام هذه الأدوية بمصاحبته من احتمالية التعرُّض لخطر الإصابة بالآثار الجانبية المُحتملة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُسمى حاصرات بيتا تُستخدم لعلاج ارتفاع ضغط الدَّم أو غيره من المشاكل القلبية (على سبيل المثال: بروبرانولول) أو لعلاج الزَرَق (المياه الزرقاء) (على سبيل المثال: تيمولول).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول أو إتراكونازول (أدوية تُستخدم لعلاج العدوى الفطرية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير أو نيلفينافير أو كوبيسيستات (أدوية تُستخدم لعلاج عدوى فيروس نقص المناعة البشري).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&zwnj;د.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمل والرضاعة</p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبكِ قبل تناوُل هذا الدَّواء. سيناقشكِ طبيبكِ حول إمكانية استخدامكِ لعقار أتكتورا بريزهيلير.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&zwnj;ه.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأثير أتكتورا بريزهيلير على القيادة واستخدام الآلات</p><p dir="RTL">&zwnj;و.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من غير المرجح أن يُؤثر هذا الدواء في قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&zwnj;ز.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معلومات هامَّة حول بعض مكونات عقار أتكتورا بريزهيلير</p><p dir="RTL"><strong>يحتوي عقار أتكتورا بريزهيلير على اللاكتوز</strong></p><p dir="RTL">يحتوي هذا الدَّواء على 25 مجم من اللاكتوز بكل كبسولة. إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل تناول هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدَّواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ما الكمية التي ينبغي استنشاقها من عقار أتكتورا بريزهيلير؟</p><p dir="RTL">هناك ثلاثة تركيزات مختلفة من عقار أتكتورا بريزهيلير كبسولات سيقرر طبيبك التَّركيز الأفضل لحالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المُعتادة هي استنشاق محتوى كبسولة واحدة كل يوم. يتعين عليك استخدام الدَّواء مرة واحدة في اليوم فقط. لا تستخدم كمية أكبر من تلك التي أخبرك طبيبك باستخدامها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك استخدام عقار أتكتورا بريزهيلير كل يوم، حتى وإن لم يسبب لك الربو مشاكل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">متى تستنشق عقار أتكتورا بريزهيلير؟</p><p dir="RTL">قم باستنشاق عقار أتكتورا بريزهيلير في نفس الوقت من كل يوم. سيُساعِد ذلك على التحكم بأعراضك ليلًا ونهارًا. سيُساعِدك ذلك أيضًا على تذكر استخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كيفية استنشاق عقار أتكتورا بريزهيلير</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار أتكتورا بريزهيلير للاستخدام عن طريق الاستنشاق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستجد في هذه العبوة جهاز استنشاق وكبسولات تحتوي على الدَّواء. يُمكِّنك جهاز الاستنشاق من استنشاق الدَّواء الموجود بالكبسولة. لا تستخدم الكبسولات إلا مع جهاز الاستنشاق المتوفر في هذه العبوة. يجب أن تظل الكبسولات في الشريط حتى تحتاج استخدامها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تدفع الكبسولة عبر الرقاقة المعدنية لإخراجها من الشريط</strong>، بل قم بإزالة الغطاء بعيدًا عن الشريط لفتحها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند البدء في استخدام عبوة جديدة، استخدم جهاز الاستنشاق الجديد المتوفر في هذه العبوة الجديدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخلص من جهاز الاستنشاق الموجود في كل عبوة بعد استخدام جميع الكبسولات الموجودة في تلك العبوة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تبتلع الكبسولات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يُرجى قراءة تعليمات الاستخدام الموجودة بالجانب الآخر من هذه النَّشرة للاطلاع على مزيد من المعلومات حول كيفية استخدام جهاز الاستنشاق</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال لم تتحسن أعراضك</strong></p><p dir="RTL">إذا لم يتحسن الربو أو إذا تفاقمت حالتك بعد بدء استخدام عقار أتكتورا بريزهيلير، فتحدَّث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا استخدمت كمية أكثر مما يجب من عقار أتكتورا بريزهيلير</p><p dir="RTL">إذا استنشقت كمية أكبر مما يجب من هذا الدَّواء بطريق الخطأ، فاتصل بطبيبك أو بالمستشفى فورًا للحصول على المشورة. فقد تحتاج إلى عناية طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أغفلت استخدام عقار أتكتورا بريزهيلير</p><p dir="RTL">إذا أغفلت استنشاق إحدى الجرعات في الموعد المُعتاد، فاستنشق جرعةً في أسرع وقت ممكن في ذلك اليوم. قم باستنشاق الجرعة التَّالية في الوقت المعتاد من اليوم التالي. لا تستنشق جرعتين في اليوم نفسه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا توقفت عن استخدام عقار أتكتورا بريزهيلير</p><p dir="RTL">لا تتوقف عن استخدام عقار أتكتورا بريزهيلير ما لم يخبرك طبيبك بذلك. قد تعاود أعراض الربو الظهور إذا توقفت عن استخدامه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء أثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض الأثار الجانبية قد تكون خطيرة</strong></p><p dir="RTL">توقف عن استخدام عقار أتكتورا بريزهيلير واحصل على المساعدة الطبية فورًا إذا أُصِبت بأيٍّ من الآتي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong><strong>: </strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>صعوبة التَّنفس أو البلع، أو تورم اللسان أو الشفتين أو الوجه، أو الطفح الجلدي، أو الحكة والشرى (أرتكاريا) (علامات تشير إلى الإصابة بتفاعل حساسية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong><strong>:</strong> قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تورُّم يصيب اللسان أو الشفتين أو الوجه أو الحَلْق بشكل أساسي (علامات مُحتَمَلة للإصابة بالوذمة الوعائية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL">تشمل الأثار الجانبية الأخرى ما يلي من المدرج أدناه. إذا أصبحت هذه الآثار الجانبية شديدة، يُرجى إخبار طبيبك، أو الصيدلي، أو الممرض(ة) الخاص(ة) بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا</strong><strong>:</strong> قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة مفاجئة من صعوبة التَّنَفُّس والشعور بضيق في الصدر مع أزيز بالصدر أو سعال</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong><strong>: </strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّر الصوت (بحة في الصوت)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأنف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عطس وسعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعضلات أو العظام أو المفاصل (علامات آلام العضلات والعظام)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong><strong>:</strong> قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع نبضات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سُلاَق فموي (علامة تشير إلى الإصابة بالكانديدا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات السُّكَّرِ في الدَّم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات عضلية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة بالجلد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعتُّم عدستي العينين (علامة تشير إلى الإصابة بالمياه البيضاء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة والشريط بعد كلمة &ldquo;EXP&rdquo;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا المنتج الدوائي لا يحتاج إلى أية شروط خاصة فيما يتعلق بدرجة حرارة التخزين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُحفَظ الكبسولات داخل الشريط الأصلي، لحمايتها من الضوء والرطوبة، ويجب ألا تُزال منه إلا قبل استخدامها مباشرةً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعَّالة هي إنداكاتيرول (في هيئة أسيتات) و موميتازون فيوروات.</p><p dir="RTL"><u>عقار أتكتورا بريزهيلير </u><u>125 </u><u>ميكروجرامًا</u><u>/62.5 </u><u>ميكروجرام</u></p><p dir="RTL">تحتوي كل كبسولة على 173 ميكروجرام إنداكاتيرول أسيتات (ما يُعادِل 150 ميكروجرام إنداكاتيرول) و80 ميكروجرام موميتازون فيوروات. تُعادِل الجرعة المُتلقاة (الجرعة التي تغادر قطعة الفم الخاصة بجهاز الاستنشاق) 125 ميكروجرام إنداكاتيرول و62.5 ميكروجرام موميتازون فيوروات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>عقار أتكتورا بريزهيلير </u><u>125 </u><u>ميكروجرامًا</u><u>/127.5 </u><u>ميكروجرام</u></p><p dir="RTL">تحتوي كل كبسولة على 173 ميكروجرام إنداكاتيرول أسيتات (ما يُعادِل 150 ميكروجرام إنداكاتيرول) و160 ميكروجرام موميتازون فيوروات. تُعادِل الجرعة المُتلقاة (الجرعة التي تغادر قطعة الفم الخاصة بجهاز الاستنشاق) 125 ميكروجرام إنداكاتيرول و127.5 ميكروجرام موميتازون فيوروات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>عقار أتكتورا بريزهيلير </u><u>125 </u><u>ميكروجرامًا</u><u>/260 </u><u>ميكروجرامًا</u></p><p dir="RTL">تحتوي كل كبسولة على 173 ميكروجرام إنداكاتيرول أسيتات (ما يُعادِل 150 ميكروجرام إنداكاتيرول) و320 ميكروجرام موميتازون فيوروات. تُعادِل الجرعة المُتلقاة (الجرعة التي تغادر قطعة الفم الخاصة بجهاز الاستنشاق) 125 ميكروجرام إنداكاتيرول و260 ميكروجرام موميتازون فيوروات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المُكَوِّن الآخر هو اللاكتوز أحادي الهيدرات (انظر &quot;يحتوي عقار أتكتورا بريزهيلير على اللاكتوز&quot; في قسم 2).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ستجد في هذه العبوة جهاز استنشاق بمصاحبة كبسولات موجودة في شرائط. الكبسولات شفافة وتحتوي على مسحوق أبيض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعقار أتكتورا بريزهيلير 125 ميكروجرامًا/62.5 ميكروجرام كبسولات رمز أزرق خاص بالمُنتَج &quot;IM150‑80&quot; مطبوع فوق شريط أزرق على الجسم مع شعار مطبوع باللون الأزرق ومُحاط بشريطين أزرقين على الغطاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعقار أتكتورا بريزهيلير 125 ميكروجرامًا/127.5 ميكروجرام كبسولات رمز رمادي خاص بالمُنتَج &quot;IM150‑160&quot; مطبوع على الجسم مع شعار مطبوع باللون الرمادي على الغطاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعقار أتكتورا بريزهيلير 125 ميكروجرامًا/260 ميكروجرامًا كبسولات رمز أسود خاص بالمُنتَج &quot;IM150‑320&quot; مطبوع فوق شريطين أسودين على الجسم مع شعار مطبوع باللون الأسود ومُحاط بشريطين أسودين على الغطاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوافر أحجام العبوات التالية:</p><p dir="RTL">عبوة واحدة تحتوي على 30 &times; 1 كبسولة صلبة مع جهاز استنشاق واحد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم آخر اعتماد لهذه النَّشرة من قِبَل منظمة الأدوية الأوروبية في 06/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder, hard capsules
Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules
Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder, hard capsules

Each capsule contains 150 mcg of indacaterol (as acetate) and 80 mcg of mometasone furoate.

Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 125 mcg of indacaterol (as acetate) and 62.5 mcg of mometasone furoate.

Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules

Each capsule contains 150 mcg of indacaterol (as acetate) and 160 mcg of mometasone furoate.

Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 125 mcg of indacaterol (as acetate) and 127.5 mcg of mometasone furoate.

Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules

Each capsule contains 150 mcg of indacaterol (as acetate) and 320 mcg of mometasone furoate.

Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 125 mcg of indacaterol (as acetate) and 260 mcg of mometasone furoate.

Excipient(s) with known effect

Each capsule contains approximately 25 mg of lactose monohydrate.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Inhalation powder, hard capsule (inhalation powder).

Atectura Breezhaler 125 micrograms/62.5 micrograms inhalation powder, hard capsules

Transparent (uncoloured) capsules containing a white powder, with the product code “IM150 80” printed in blue above one blue bar on the body and with the product logo printed in blue and surrounded by two blue bars on the cap.

Atectura Breezhaler 125 micrograms/127.5 micrograms inhalation powder, hard capsules

Transparent (uncoloured) capsules containing a white powder, with the product code “IM150 160” printed in grey on the body and with the product logo printed in grey on the cap.

Atectura Breezhaler 125 micrograms/260 micrograms inhalation powder, hard capsules

Transparent (uncoloured) capsules containing a white powder, with the product code “IM150 320” printed in black above two black bars on the body and with the product logo printed in black and surrounded by two black bars on the cap.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12&nbsp;years of age and older not adequately controlled with inhaled corticosteroids and inhaled short‑acting beta<sub>2</sub>‑agonists.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Adults and adolescents aged 12&nbsp;years and over</u></em></p><p>The recommended dose is one capsule to be inhaled once daily.</p><p>&nbsp;</p><p>Patients should be given the strength containing the appropriate mometasone furoate dosage for the severity of their disease and should be regularly reassessed by a healthcare professional.</p><p>&nbsp;</p><p>The maximum recommended dose is 125&nbsp;mcg/260&nbsp;mcg once daily.</p><p>&nbsp;</p><p>Treatment should be administered at the same time of the day each day. It can be administered irrespective of the time of the day. If a dose is missed, it should be taken as soon as possible. Patients should be instructed not to take more than one dose in a day.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Elderly population</em></p><p>No dose adjustment is required in elderly patients (65&nbsp;years of age or older) (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is required in patients with renal impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is required in patients with mild or moderate hepatic impairment. No data are available for the use of the medicinal product in patients with severe hepatic impairment, therefore it should be used in these patients only if the expected benefit outweighs the potential risk (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The posology in patients 12&nbsp;years of age and older is the same posology as in adults. The safety and efficacy in paediatric patients below 12&nbsp;years of age have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>For inhalation use only. The capsules must not be swallowed.</p><p>&nbsp;</p><p>The capsules must be administered only using the inhaler provided (see section&nbsp;6.6) with each new prescription.</p><p>&nbsp;</p><p>Patients should be instructed on how to administer the medicinal product correctly. Patients who do not experience improvement in breathing should be asked if they are swallowing the medicinal product rather than inhaling it.</p><p>&nbsp;</p><p>The capsules must only be removed from the blister immediately before use.</p><p>&nbsp;</p><p>After inhalation, patients should rinse their mouth with water without swallowing (see sections&nbsp;4.4 and 6.6).</p><p>&nbsp;</p><p>For instructions on use of the medicinal product before administration, see section&nbsp;6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Deterioration of disease</u></p><p>&nbsp;</p><p>This medicinal product should not be used to treat acute asthma symptoms, including acute episodes of bronchospasm, for which a short‑acting bronchodilator is required. Increasing use of short‑acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician.</p><p>&nbsp;</p><p>Patients should not stop treatment without physician supervision since symptoms may recur after discontinuation.</p><p>&nbsp;</p><p>It is recommended that treatment with this medicinal product should not be stopped abruptly. If patients find the treatment ineffective, they should continue treatment but must seek medical attention. Increasing use of reliever bronchodilators indicates a worsening of the underlying condition and warrants a reassessment of the therapy. Sudden and progressive deterioration in the symptoms of asthma is potentially life‑threatening and the patient should undergo urgent medical assessment.</p><p>&nbsp;</p><p><u>Hypersensitivity</u></p><p>&nbsp;</p><p>Immediate hypersensitivity reactions have been observed after administration of this medicinal product. If signs suggesting allergic reactions occur, in particular angioedema (including difficulties in breathing or swallowing, swelling of the tongue, lips and face), urticaria or skin rash, treatment should be discontinued immediately and alternative therapy instituted.</p><p>&nbsp;</p><p><u>Paradoxical bronchospasm</u></p><p>&nbsp;</p><p>As with other inhalation therapy, administration of this medicinal product may result in paradoxical bronchospasm, which can be life‑threatening. If this occurs, treatment should be discontinued immediately and alternative therapy instituted.</p><p>&nbsp;</p><p><u>Cardiovascular effects of beta agonists</u></p><p>&nbsp;</p><p>Like other medicinal products containing beta<sub>2</sub>‑adrenergic agonists, this medicinal product may produce a clinically significant cardiovascular effect in some patients, as measured by increases in pulse rate, blood pressure and/or symptoms. If such effects occur, treatment may need to be discontinued.</p><p>&nbsp;</p><p>This medicinal product should be used with caution in patients with cardiovascular disorders (coronary artery disease, acute myocardial infarction, cardiac arrhythmias, hypertension), convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta<sub>2</sub>‑adrenergic agonists.</p><p>&nbsp;</p><p>Patients with unstable ischaemic heart disease, a history of myocardial infarction in last 12&nbsp;months, New York Heart Association (NYHA) class&nbsp;III/IV left ventricular failure, arrhythmia, uncontrolled hypertension, cerebrovascular disease or history of long QT syndrome and patients being treated with medicinal products known to prolong QTc were excluded from studies in the indacaterol/mometasone furoate clinical development programme. Thus safety outcomes in these populations are considered unknown.</p><p>&nbsp;</p><p>While beta<sub>2</sub>‑adrenergic agonists have been reported to produce electrocardiographic (ECG) changes, such as flattening of the T wave, prolongation of QT interval and ST segment depression, the clinical significance of these observations is unknown.</p><p>&nbsp;</p><p>Long‑acting beta<sub>2</sub>‑adrenergic agonists (LABA) or LABA‑containing combination products such as Atectura Breezhaler should therefore be used with caution in patients with known or suspected prolongation of the QT interval or who are being treated with medicinal products affecting the QT interval.</p><p>&nbsp;</p><p><u>Hypokalaemia with beta agonists</u></p><p>&nbsp;</p><p>Beta<sub>2</sub>‑adrenergic agonists may produce significant hypokalaemia in some patients, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. In patients with severe asthma hypokalaemia may be potentiated by hypoxia and concomitant treatment, which may increase the susceptibility to cardiac arrhythmias (see section&nbsp;4.5).</p><p>&nbsp;</p><p>Clinically relevant hypokalaemia has not been observed in clinical studies of indacaterol/mometasone furoate at the recommended therapeutic dose.</p><p>&nbsp;</p><p><u>Hyperglycaemia</u></p><p>&nbsp;</p><p>Inhalation of high doses of beta<sub>2</sub>‑adrenergic agonists and corticosteroids may produce increases in plasma glucose. Upon initiation of treatment, plasma glucose should be monitored more closely in diabetic patients.</p><p>&nbsp;</p><p>This medicinal product has not been investigated in patients with Type&nbsp;I diabetes mellitus or uncontrolled Type&nbsp;II diabetes mellitus.</p><p>&nbsp;</p><p><u>Prevention of oropharyngeal infections</u></p><p>&nbsp;</p><p>In order to reduce the risk of oropharyngeal candida infection, patients should be advised to rinse their mouth or gargle with water without swallowing it or brush their teeth after inhaling the prescribed dose.</p><p>&nbsp;</p><p><u>Systemic effects of corticosteroids</u></p><p>&nbsp;</p><p>Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for prolonged periods. These effects are much less likely to occur than with oral corticosteroids and may vary in individual patients and between different corticosteroid preparations.</p><p>&nbsp;</p><p>Possible systemic effects may include Cushing&rsquo;s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataracts, glaucoma, and, more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). It is therefore important that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control of asthma is maintained.</p><p>&nbsp;</p><p>Visual disturbance may be reported with systemic and topical (including intranasal, inhaled and intraocular) corticosteroid use. Patients presenting with symptoms such as blurred vision or other visual disturbances should be considered for referral to an ophthalmologist for evaluation of possible causes of visual disturbances, which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.</p><p>&nbsp;</p><p>This medicinal product should be administered with caution in patients with pulmonary tuberculosis or in patients with chronic or untreated infections.</p><p>&nbsp;</p><p><u>Excipients</u></p><p><u>&nbsp;</u></p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose‑galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific interaction studies were conducted with indacaterol/mometasone furoate. Information on the potential for interactions is based on the potential for each of the monotherapy components.</p><p>&nbsp;</p><p><u>Medicinal products known to prolong the QTc interval</u></p><p>&nbsp;</p><p>Like other medicinal products containing a beta<sub>2</sub>‑adrenergic agonist, this medicinal product should be administered with caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants or medicinal products known to prolong the QT interval, as any effect of these on the QT interval may be potentiated. Medicinal products known to prolong the QT interval may increase the risk of ventricular arrhythmia (see sections&nbsp;4.4 and 5.1).</p><p>&nbsp;</p><p><u>Hypokalaemic treatment</u></p><p>&nbsp;</p><p>Concomitant hypokalaemic treatment with methylxanthine derivatives, steroids or non‑potassium‑sparing diuretics may potentiate the possible hypokalaemic effect of beta<sub>2</sub>‑adrenergic agonists (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Beta‑</u><u>adrenergic blockers</u></p><p>&nbsp;</p><p>Beta‑adrenergic blockers may weaken or antagonise the effect of beta<sub>2</sub>‑adrenergic agonists. Therefore, this medicinal product should not be given together with beta‑adrenergic blockers unless there are compelling reasons for their use. Where required, cardioselective beta‑adrenergic blockers should be preferred, although they should be administered with caution.</p><p>&nbsp;</p><p><u>Interaction with CYP3A4 and P‑glycoprotein inhibitors</u></p><p>&nbsp;</p><p>Inhibition of CYP3A4 and P‑glycoprotein (P‑gp) has no impact on the safety of therapeutic doses of Atectura Breezhaler.</p><p>&nbsp;</p><p>Inhibition of the key contributors of indacaterol clearance (CYP3A4 and P‑gp) or mometasone furoate clearance (CYP3A4) raises the systemic exposure of indacaterol or mometasone furoate up to two‑fold.</p><p>&nbsp;</p><p>Due to the very low plasma concentration achieved after inhaled dosing, clinically significant interactions with mometasone furoate are unlikely. However, there may be a potential for increased systemic exposure to mometasone furoate when strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, nelfinavir, ritonavir, cobicistat) are co‑administered.</p><p>&nbsp;</p><p><u>Other long‑acting beta<sub>2</sub>‑adrenergic agonists</u></p><p>&nbsp;</p><p>The co‑administration of this medicinal product with other medicinal products containing long‑acting beta<sub>2</sub>‑adrenergic agonists has not been studied and is not recommended as it may potentiate adverse reactions (see sections&nbsp;4.8 and 4.9).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are insufficient data from the use of Atectura Breezhaler or its individual components (indacaterol and mometasone furoate) in pregnant women to determine whether there is a risk.</p><p>&nbsp;</p><p>Indacaterol was not teratogenic in rats and rabbits following subcutaneous administration (see section&nbsp;5.3). In animal reproduction studies with pregnant mice, rats and rabbits, mometasone furoate caused increased foetal malformations and decreased foetal survival and growth.</p><p>&nbsp;</p><p>Like other medicinal products containing beta<sub>2</sub>‑adrenergic agonists, indacaterol may inhibit labour due to a relaxant effect on uterine smooth muscle.</p><p>&nbsp;</p><p>This medicinal product should only be used during pregnancy if the expected benefit to the patient justifies the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>There is no information available on the presence of indacaterol or mometasone furoate in human milk, on the effects on a breast‑fed infant, or on the effects on milk production. Other inhaled corticosteroids similar to mometasone furoate are transferred into human milk. Indacaterol (including its metabolites) and mometasone furoate have been detected in the milk of lactating rats.</p><p>&nbsp;</p><p>A decision must be made whether to discontinue breast‑feeding or to discontinue/abstain from therapy, taking into account the benefit of breast‑feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Reproduction studies and other data in animals did not indicate a concern regarding fertility in either males or females.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most common adverse reactions over 52&nbsp;weeks were asthma (exacerbation) (26.9%), nasopharyngitis (12.9%), upper respiratory tract infection (5.9%) and headache (5.8%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse drug reactions (ADRs) are listed by MedDRA system organ class (Table&nbsp;1). The frequency of the ADRs is based on the PALLADIUM study. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><p>&nbsp;</p><p><strong>Table&nbsp;1 Adverse reactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr><tr><td rowspan="3"><p>Infections and infestations</p></td><td><p>Nasopharyngitis</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Candidiasis*<sup>1</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2"><p>Immune system disorders</p></td><td><p>Hypersensitivity*<sup>2</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Angioedema*<sup>3</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Hyperglycaemia*<sup>4</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache*<sup>5</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cataract*<sup>6</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Tachycardia*<sup>7</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="3"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>Asthma (exacerbation)</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p>Oropharyngeal pain*<sup>8</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Dysphonia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="2"><p>Skin and subcutaneous tissue disorders</p></td><td><p>Rash*<sup>9</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td><p>Pruritus*<sup>10</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2"><p>Musculoskeletal and connective tissue disorders</p></td><td><p>Musculoskeletal pain*<sup>11</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td><p>Muscle spasms</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Indicates grouping of preferred terms (PTs):</p><p>1 Oral candidiasis, oropharyngeal candidiasis.</p><p>2 Drug eruption, drug hypersensitivity, hypersensitivity, rash, rash erythematous, rash pruritic, urticaria.</p><p>3 Allergic oedema, angioedema, periorbital swelling, swelling of eyelid.</p><p>4 Blood glucose increased, hyperglycaemia.</p><p>5 Headache, tension headache.</p><p>6 Cataract, cataract cortical.</p><p>7 Heart rate increased, tachycardia, sinus tachycardia, supraventricular tachycardia.</p><p>8 Oral pain, oropharyngeal discomfort, oropharyngeal pain, throat irritation, odynophagia.</p><p>9 Drug eruption, rash, rash erythematous, rash pruritic.</p><p>10 Anal pruritus, eye pruritus, nasal pruritus, pruritus, pruritus genital.</p><p>11 Back pain, musculoskeletal pain, myalgia, neck pain, musculoskeletal chest pain.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>To report any side effect(s):</u></p><p>&bull;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General supportive measures and symptomatic treatment should be initiated in cases of suspected overdose.</p><p>&nbsp;</p><p>An overdose will likely produce signs, symptoms or adverse effects associated with the pharmacological actions of the individual components (e.g. tachycardia, tremor, palpitations, headache, nausea, vomiting, drowsiness, ventricular arrhythmias, metabolic acidosis, hypokalaemia, hyperglycaemia, suppression of hypothalamic pituitary adrenal axis function).</p><p>&nbsp;</p><p>Use of cardioselective beta blockers may be considered for treating beta<sub>2</sub>‑adrenergic effects, but only under the supervision of a physician and with extreme caution, since the use of beta<sub>2</sub>‑adrenergic blockers may provoke bronchospasm. In serious cases, patients should be hospitalised.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for obstructive airway diseases, adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics, ATC code: R03AK14</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>This medicinal product is a combination of indacaterol, a long‑acting beta<sub>2</sub>‑adrenergic agonist (LABA), and mometasone furoate, an inhaled synthetic corticosteroid (ICS).</p><p>&nbsp;</p><p><em><u>Indacaterol</u></em></p><p>The pharmacological effects of beta<sub>2</sub>‑adrenoceptor agonists, including indacaterol, are at least in part attributable to increased cyclic‑3&rsquo;, 5&rsquo;‑adenosine monophosphate (cyclic AMP) levels, which cause relaxation of bronchial smooth muscle.</p><p>&nbsp;</p><p>When inhaled, indacaterol acts locally in the lung as a bronchodilator. Indacaterol is a partial agonist at the human beta<sub>2</sub>‑adrenergic receptor with nanomolar potency. In isolated human bronchus, indacaterol has a rapid onset of action and a long duration of action.</p><p>&nbsp;</p><p>Although beta<sub>2</sub>‑adrenergic receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta<sub>1</sub>‑receptors are the predominant receptors in the human heart, there are also beta<sub>2</sub>‑adrenergic receptors in the human heart comprising 10% to 50% of the total adrenergic receptors.</p><p>&nbsp;</p><p><em><u>Mometasone furoate</u></em></p><p>Mometasone furoate is a synthetic corticosteroid with high affinity for glucocorticoid receptors and local anti‑inflammatory properties. <em>In vitro</em>, mometasone furoate inhibits the release of leukotrienes from leukocytes of allergic patients. In cell culture, mometasone furoate demonstrated high potency in inhibition of synthesis and release of IL‑1, IL‑5, IL‑6 and TNF‑alpha. It is also a potent inhibitor of leukotriene production and of the production of the Th2 cytokines IL‑4 and IL‑5 from human CD4+ T‑cells.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>The pharmacodynamic response profile of this medicinal product is characterised by rapid onset of action within 5&nbsp;minutes after dosing and sustained effect over the 24‑hour dosing interval, as evidenced by improvements in trough forced expiratory volume in the first second (FEV<sub>1</sub>) improvements versus comparators 24&nbsp;hours after dosing.</p><p>&nbsp;</p><p>No tachyphylaxis to the lung function benefits of this medicinal product was observed over time.</p><p>&nbsp;</p><p><em><u>QTc interval</u></em></p><p>The effect of this medicinal product on the QTc interval has not been evaluated in a thorough QT (TQT) study. For mometasone furoate, no QTc‑prolonging properties are known.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>Two phase&nbsp;III randomised, double‑blind studies (PALLADIUM and QUARTZ) of different durations evaluated the safety and efficacy of Atectura Breezhaler in adult and adolescent patients with persistent asthma.</p><p>&nbsp;</p><p>The PALLADIUM study was a 52‑week pivotal study evaluating Atectura Breezhaler 125&nbsp;mcg/127.5&nbsp;mcg once daily (N=439) and 125&nbsp;mcg/260&nbsp;mcg once daily (N=445) compared to mometasone furoate 400&nbsp;mcg once daily (N=444) and 800&nbsp;mcg per day (given as 400&nbsp;mcg twice daily) (N=442), respectively. A third active control arm included subjects treated with salmeterol/fluticasone propionate 50&nbsp;mcg/500&nbsp;mcg twice daily (N=446). All subjects were required to have symptomatic asthma (ACQ‑7 score &ge;1.5) and were on asthma maintenance therapy using an inhaled synthetic corticosteroid (ICS) with or without LABA for at least 3&nbsp;months prior to study entry. At screening, 31% of patients had history of exacerbation in the previous year. At study entry, the most common asthma medications reported were medium dose of ICS (20%), high dose of ICS (7%) or low dose of ICS in combination with a LABA (69%).</p><p>&nbsp;</p><p>The primary objective of the study was to demonstrate superiority of either Atectura Breezhaler 125&nbsp;mcg/127.5&nbsp;mcg once daily over mometasone furoate 400&nbsp;mcg once daily or Atectura Breezhaler 125&nbsp;mcg/260&nbsp;mcg once daily over mometasone furoate 400&nbsp;mcg twice daily in terms of trough FEV<sub>1</sub> at week&nbsp;26.</p><p>&nbsp;</p><p>At week&nbsp;26, Atectura Breezhaler 125&nbsp;mcg/127.5&nbsp;mcg and 125&nbsp;mcg/260&nbsp;mcg once daily both demonstrated statistically significant improvements in trough FEV<sub>1</sub> and Asthma Control Questionnaire (ACQ‑7) score compared to mometasone furoate 400&nbsp;mcg once or twice daily, respectively (see Table&nbsp;2). Findings at week&nbsp;52 were consistent with week&nbsp;26.</p><p>&nbsp;</p><p>Atectura Breezhaler 125&nbsp;mcg/127.5&nbsp;mcg and 125&nbsp;mcg/260&nbsp;mcg once daily both demonstrated a clinically meaningful reduction in the annual rate of moderate or severe exacerbations (secondary endpoint), compared to mometasone furoate 400&nbsp;mcg once and twice daily (see Table&nbsp;2).</p><p>&nbsp;</p><p>Results for the most clinically relevant endpoints are described in Table&nbsp;2.</p><p>&nbsp;</p><p><em>Lung function, symptoms and exacerbations</em></p><p>&nbsp;</p><p>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Results of primary and secondary endpoints in PALLADIUM study at weeks&nbsp;26 and 52</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Time point/<br />Duration</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Atectura Breezhaler<sup>1</sup></strong></p><p><strong>vs MF<sup>2</sup></strong></p></td><td style="vertical-align:top"><p><strong>Atectura Breezhaler<sup>1</sup></strong></p><p><strong>vs SAL/FP<sup>3</sup></strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Medium dose vs</p><p>medium dose</p></td><td style="vertical-align:top"><p>High dose vs</p><p>high dose</p></td><td style="vertical-align:top"><p>High dose vs</p><p>high dose</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Lung function</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Trough FEV<sub>1</sub><sup>4</sup></em></p></td></tr><tr><td rowspan="2"><p>Treatment difference</p><p>P value</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>Week&nbsp;26</p><p>(primary endpoint)</p></td><td style="vertical-align:top"><p>211&nbsp;ml</p><p>&lt;0.001</p><p>(167, 255)</p></td><td style="vertical-align:top"><p>132&nbsp;ml</p><p>&lt;0.001</p><p>(88, 176)</p></td><td style="vertical-align:top"><p>36&nbsp;ml</p><p>0.101</p><p>(‑7, 80)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>209&nbsp;ml</p><p>&lt;0.001</p><p>(163, 255)</p></td><td style="vertical-align:top"><p>136&nbsp;ml</p><p>&lt;0.001</p><p>(90, 183)</p></td><td style="vertical-align:top"><p>48&nbsp;ml</p><p>0.040</p><p>(2, 94)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Mean morning peak expiratory flow (PEF)*</em></p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>30.2&nbsp;l/min</p><p>(24.2, 36.3)</p></td><td style="vertical-align:top"><p>28.7&nbsp;l/min</p><p>(22.7, 34.8)</p></td><td style="vertical-align:top"><p>13.8&nbsp;l/min</p><p>(7.7, 19.8)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Mean evening peak expiratory flow (PEF)*</em></p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>29.1&nbsp;l/min</p><p>(23.3, 34.8)</p></td><td style="vertical-align:top"><p>23.7&nbsp;l/min</p><p>(18.0, 29.5)</p></td><td style="vertical-align:top"><p>9.1&nbsp;l/min</p><p>(3.3, 14.9)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Symptoms</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>ACQ‑7</em></p></td></tr><tr><td rowspan="2"><p>Treatment difference</p><p>P value</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>Week&nbsp;26</p><p>(key secondary endpoint)</p></td><td style="vertical-align:top"><p>‑0.248</p><p>&lt;0.001</p><p>(‑0.334, ‑0.162)</p></td><td style="vertical-align:top"><p>‑0.171</p><p>&lt;0.001</p><p>(‑0.257, ‑0.086)</p></td><td style="vertical-align:top"><p>‑0.054</p><p>0.214</p><p>(‑0.140, 0.031)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>‑0.266</p><p>(‑0.354, ‑0.177)</p></td><td style="vertical-align:top"><p>‑0.141</p><p>(‑0.229, ‑0.053)</p></td><td style="vertical-align:top"><p>0.010</p><p>(‑0.078, 0.098)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>ACQ responders (percentage of patients achieving minimal clinical important difference (MCID) from baseline with ACQ &ge;0.5)</em></p></td></tr><tr><td style="vertical-align:top"><p>Percentage</p></td><td style="vertical-align:top"><p>Week&nbsp;26</p></td><td style="vertical-align:top"><p>76% vs 67%</p></td><td style="vertical-align:top"><p>76% vs 72%</p></td><td style="vertical-align:top"><p>76% vs 76%</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>Week&nbsp;26</p></td><td style="vertical-align:top"><p>1.73</p><p>(1.26, 2.37)</p></td><td style="vertical-align:top"><p>1.31</p><p>(0.95, 1.81)</p></td><td style="vertical-align:top"><p>1.06</p><p>(0.76, 1.46)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Percentage</p></td><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>82% vs 69%</p></td><td style="vertical-align:top"><p>78% vs 74%</p></td><td style="vertical-align:top"><p>78% vs 77%</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>2.24</p><p>(1.58, 3.17)</p></td><td style="vertical-align:top"><p>1.34</p><p>(0.96, 1.87)</p></td><td style="vertical-align:top"><p>1.05</p><p>(0.75, 1.49)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Percentage of rescue medication free days*</em></p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>8.6</p><p>(4.7, 12.6)</p></td><td style="vertical-align:top"><p>9.6</p><p>(5.7, 13.6)</p></td><td style="vertical-align:top"><p>4.3</p><p>(0.3, 8.3)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Percentage of days with no symptoms*</em></p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>9.1</p><p>(4.6, 13.6)</p></td><td style="vertical-align:top"><p>5.8</p><p>(1.3, 10.2)</p></td><td style="vertical-align:top"><p>3.4</p><p>(‑1.1, 7.9)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Annualised rate of asthma exacerbations**</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Moderate or severe exacerbations</em></p></td></tr><tr><td style="vertical-align:top"><p>AR</p></td><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>0.27 vs 0.56</p></td><td style="vertical-align:top"><p>0.25 vs 0.39</p></td><td style="vertical-align:top"><p>0.25 vs 0.27</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>RR</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>0.47</p><p>(0.35, 0.64)</p></td><td style="vertical-align:top"><p>0.65</p><p>(0.48, 0.89)</p></td><td style="vertical-align:top"><p>0.93</p><p>(0.67, 1.29)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><em>Severe exacerbations</em></p></td></tr><tr><td style="vertical-align:top"><p>AR</p></td><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>0.13 vs 0.29</p></td><td style="vertical-align:top"><p>0.13 vs 0.18</p></td><td style="vertical-align:top"><p>0.13 vs 0.14</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>RR</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>Week&nbsp;52</p></td><td style="vertical-align:top"><p>0.46</p><p>(0.31, 0.67)</p></td><td style="vertical-align:top"><p>0.71</p><p>(0.47, 1.08)</p></td><td style="vertical-align:top"><p>0.89</p><p>(0.58, 1.37)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean value for the treatment duration</p><p>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RR &lt;1.00 favours indacaterol/mometasone furoate.</p><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atectura Breezhaler medium dose: 125&nbsp;mcg/127.5&nbsp;mcg od; high dose: 125&nbsp;mcg/260&nbsp;mcg od.</p><p><sup>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>MF: mometasone furoate medium dose: 400&nbsp;mcg od; high dose: 400&nbsp;mcg bid (content doses).</p><p>Mometasone furoate 127.5&nbsp;mcg od and 260&nbsp;mcg od in Atectura Breezhaler are comparable to mometasone furoate 400&nbsp;mcg od and 800&nbsp;mcg per day (given as 400&nbsp;mcg bid).</p><p><sup>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>SAL/FP: salmeterol/fluticasone propionate high dose: 50&nbsp;mcg/500&nbsp;mcg bid (content dose).</p><p><sup>4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Trough FEV<sub>1</sub>: the mean of the two FEV<sub>1</sub> values measured at 23&nbsp;hours 15&nbsp;min and 23&nbsp;hours 45&nbsp;min after the evening dose.</p><p>Primary endpoint (trough FEV<sub>1</sub> at week&nbsp;26) and key secondary endpoint (ACQ‑7 score at week&nbsp;26) were part of confirmatory testing strategy and thus controlled for multiplicity. All other endpoints were not part of confirmatory testing strategy.</p><p>RR = rate ratio, AR = annualised rate</p><p>od = once daily, bid = twice daily</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Pre‑specified pooled analysis</u></p><p>&nbsp;</p><p>Atectura Breezhaler 125&nbsp;mcg/260&nbsp;mcg once daily was also studied as an active comparator in another phase&nbsp;III study (IRIDIUM) in which all subjects had a history of asthma exacerbation requiring systemic corticosteroids in the past year. A pre‑specified pooled analysis across the IRIDIUM and PALLADIUM studies was conducted to compare Atectura Breezhaler 125&nbsp;mcg/260&nbsp;mcg once daily to salmeterol/fluticasone 50&nbsp;mcg/500&nbsp;mcg twice daily for the endpoints of trough FEV<sub>1</sub> and ACQ‑7 at week&nbsp;26 and annualised rate of exacerbations. The pooled analysis demonstrated that Atectura Breezhaler improved trough FEV<sub>1</sub> by 43&nbsp;ml (95% CI: 17, 69) and ACQ‑7 score by ‑0.091 (95% CI: ‑0.153, ‑0.030) at week&nbsp;26 and reduced the annualised rate of moderate or severe asthma exacerbations by 22% (RR: 0.78; 95% CI: 0.66, 0.93) and of severe exacerbations by 26% (RR: 0.74; 95% CI: 0.61, 0.91) versus salmeterol/fluticasone.</p><p>&nbsp;</p><p>The QUARTZ study was a 12‑week study evaluating Atectura Breezhaler 125&nbsp;mcg/62.5&nbsp;mcg once daily (N=398) compared to mometasone furoate 200&nbsp;mcg once daily (N=404). All subjects were required to be symptomatic and on asthma maintenance therapy using a low‑dose ICS (with or without LABA) for at least 1&nbsp;month prior to study entry. At study entry, the most common asthma medications reported were low‑dose ICS (43%) and LABA/low‑dose ICS (56%). The primary endpoint of the study was to demonstrate superiority of Atectura Breezhaler 125&nbsp;mcg/62.5&nbsp;mcg once daily over mometasone furoate 200&nbsp;mcg once daily in terms of trough FEV<sub>1</sub> at week&nbsp;12.</p><p>&nbsp;</p><p>Atectura Breezhaler 125&nbsp;mcg/62.5&nbsp;mcg once daily demonstrated a statistically significant improvement in baseline trough FEV<sub>1</sub> at week&nbsp;12 and Asthma Control Questionnaire (ACQ‑7) score compared to mometasone furoate 200&nbsp;mcg once daily.</p><p>&nbsp;</p><p>Results for the most clinically relevant endpoints are described in Table&nbsp;3.</p><p>&nbsp;</p><p>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Results of primary and secondary endpoints in QUARTZ study at week&nbsp;12</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:622px"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Atectura Breezhaler low dose* vs</strong></p><p><strong>MF low dose**</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Lung function</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Trough FEV<sub>1</sub> (primary endpoint)***</em></p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p><p>P value</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>182&nbsp;ml</p><p>&lt;0.001</p><p>(148, 217)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Mean morning peak expiratory flow (PEF)</em></p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>27.2&nbsp;l/min</p><p>(22.1, 32.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Evening peak expiratory flow (PEF)</em></p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>26.1&nbsp;l/min</p><p>(21.0, 31.2)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Symptoms</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>ACQ‑7 (key secondary endpoint)</em></p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p><p>P value</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>‑0.218</p><p>&lt;0.001</p><p>(‑0.293, ‑0.143)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Percentage of patients achieving MCID from baseline with ACQ &ge;0.5</em></p></td></tr><tr><td style="vertical-align:top"><p>Percentage</p><p>Odds ratio</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>75% vs 65%</p><p>1.69</p><p>(1.23, 2.33)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Percentage of rescue medication free days</em></p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>8.1</p><p>(4.3, 11.8)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><em>Percentage of days with no symptoms</em></p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>2.7</p><p>&nbsp;(‑1.0, 6.4)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atectura Breezhaler low dose: 125/62.5&nbsp;mcg od.</p><p>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MF: mometasone furoate low dose: 200&nbsp;mcg od (content dose).</p><p>Mometasone furoate 62.5&nbsp;mcg in Atectura Breezhaler od is comparable to mometasone furoate 200&nbsp;mcg od (content dose).</p><p>***&nbsp;&nbsp;&nbsp; Trough FEV<sub>1</sub>: the mean of the two FEV<sub>1</sub> values measured at 23&nbsp;hours 15&nbsp;min and 23&nbsp;hours 45&nbsp;min after the evening dose.</p><p>od = once daily, bid = twice daily</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>In the PALLADIUM study, which included 106&nbsp;adolescents (12‑17&nbsp;years old), the improvements in trough FEV<sub>1</sub> at week&nbsp;26 were 0.173&nbsp;litres (95% CI: ‑0.021, 0.368) for Atectura Breezhaler 125&nbsp;mcg/260&nbsp;mcg once daily vs mometasone furoate 800&nbsp;mcg (i.e. high doses) and 0.397&nbsp;litres (95% CI: 0.195, 0.599) for Atectura Breezhaler 125&nbsp;mcg/127.5&nbsp;mcg once daily vs mometasone furoate 400&nbsp;mcg once daily (i.e. medium doses).</p><p>&nbsp;</p><p>In the QUARTZ study, which included 63&nbsp;adolescents (12‑17&nbsp;years old), the Least Square means treatment difference for trough FEV<sub>1</sub> at day&nbsp;85 (week&nbsp;12) was 0.251&nbsp;litres (95% CI: 0.130, 0.371).</p><p>&nbsp;</p><p>For the adolescent subgroups, improvements in lung function, symptoms and exacerbation reductions were consistent with the overall population.</p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with indacaterol/mometasone furoate in one or more subsets of the paediatric population in asthma (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Following inhalation of Atectura Breezhaler, the median time to reach peak plasma concentrations of indacaterol and mometasone furoate was approximately 15&nbsp;minutes and 1&nbsp;hour, respectively.</p><p>&nbsp;</p><p>Based on the <em>in vitro</em> performance data, the dose of each of the monotherapy components delivered to the lung is expected to be similar for the indacaterol/mometasone furoate combination and the monotherapy products. Steady‑state plasma exposure to indacaterol and mometasone furoate after inhalation of the combination was similar to the systemic exposure after inhalation of indacaterol maleate or mometasone furoate as monotherapy products.</p><p>&nbsp;</p><p>Following inhalation of the combination, the absolute bioavailability was estimated to be about 45% for indacaterol and less than 10% for mometasone furoate.</p><p>&nbsp;</p><p><em><u>Indacaterol</u></em></p><p>Indacaterol concentrations increased with repeated once‑daily administration. Steady state was achieved within 12 to 14&nbsp;days. The mean accumulation ratio of indacaterol, i.e. AUC over the 24‑h dosing interval on day&nbsp;14 compared to day&nbsp;1, was in the range of 2.9 to 3.8 for once‑daily inhaled doses between 60 and 480&nbsp;mcg (delivered dose). Systemic exposure results from a composite of pulmonary and gastrointestinal absorption; about 75% of systemic exposure was from pulmonary absorption and about 25% from gastrointestinal absorption.</p><p>&nbsp;</p><p><em><u>Mometasone furoate</u></em></p><p>Mometasone furoate concentrations increased with repeated once‑daily administration via the Breezhaler inhaler. Steady state was achieved after 12&nbsp;days. The mean accumulation ratio of mometasone furoate, i.e. AUC over the 24‑h dosing interval on day&nbsp;14 compared to day&nbsp;1, was in the range of 1.61 to 1.71 for once‑daily inhaled doses between 62.5 and 260&nbsp;mcg as part of the indacaterol/mometasone furoate combination.</p><p>&nbsp;</p><p>Following oral administration of mometasone furoate, the absolute oral systemic bioavailability of mometasone furoate was estimated to be very low (&lt;2%).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p><em><u>Indacaterol</u></em></p><p>After intravenous infusion the volume of distribution (V<sub>z</sub>) of indacaterol was 2,361 to 2,557&nbsp;litres, indicating an extensive distribution. The <em>in vitro</em> human serum and plasma protein binding were 94.1 to 95.3% and 95.1 to 96.2%, respectively.</p><p>&nbsp;</p><p><em><u>Mometasone furoate</u></em></p><p>After intravenous bolus administration, the V<sub>d</sub> is 332&nbsp;litres. The <em>in vitro</em> protein binding for mometasone furoate is high, 98% to 99% in concentration range of 5 to 500&nbsp;ng/ml.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p><em><u>Indacaterol</u></em></p><p>After oral administration of radiolabelled indacaterol in a human ADME (absorption, distribution, metabolism, excretion) study, unchanged indacaterol was the main component in serum, accounting for about one third of total drug‑related AUC over 24&nbsp;hours. A hydroxylated derivative was the most prominent metabolite in serum. Phenolic O‑glucuronides of indacaterol and hydroxylated indacaterol were further prominent metabolites. A diastereomer of the hydroxylated derivative, an N‑glucuronide of indacaterol, and C‑ and N‑dealkylated products were further metabolites identified.</p><p>&nbsp;</p><p><em>In vitro</em> investigations indicated that UGT1A1 was the only UGT isoform that metabolised indacaterol to the phenolic O‑glucuronide. The oxidative metabolites were found in incubations with recombinant CYP1A1, CYP2D6 and CYP3A4. CYP3A4 is concluded to be the predominant isoenzyme responsible for hydroxylation of indacaterol. <em>In vitro</em> investigations further indicated that indacaterol is a low‑affinity substrate for the efflux pump P‑gp.</p><p>&nbsp;</p><p><em>In vitro</em> the UGT1A1 isoform is a major contributor to the metabolic clearance of indacaterol. However, as shown in a clinical study in populations with different UGT1A1 genotypes, systemic exposure to indacaterol is not significantly affected by the UGT1A1 genotype.</p><p>&nbsp;</p><p><em><u>Mometasone furoate</u></em></p><p>The portion of an inhaled mometasone furoate dose that is swallowed and absorbed in the gastrointestinal tract undergoes extensive metabolism to multiple metabolites. There are no major metabolites detectable in plasma. In human liver microsomes mometasone furoate is metabolised by CYP3A4.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p><em><u>Indacaterol</u></em></p><p>In clinical studies which included urine collection, the amount of indacaterol excreted unchanged via urine was generally lower than 2% of the dose. Renal clearance of indacaterol was, on average, between 0.46 and 1.20&nbsp;litres/hour. Compared with the serum clearance of indacaterol of 18.8 to 23.3&nbsp;litres/hour, it is evident that renal clearance plays a minor role (about 2 to 6% of systemic clearance) in the elimination of systemically available indacaterol.</p><p>&nbsp;</p><p>In a human ADME study in which indacaterol was given orally, the faecal route of excretion was dominant over the urinary route. Indacaterol was excreted into human faeces primarily as unchanged parent substance (54% of the dose) and, to a lesser extent, hydroxylated indacaterol metabolites (23% of the dose). Mass balance was complete with &ge;90% of the dose recovered in the excreta.</p><p>&nbsp;</p><p>Indacaterol serum concentrations declined in a multi‑phasic manner with an average terminal half‑life ranging from 45.5 to 126&nbsp;hours. The effective half‑life, calculated from the accumulation of indacaterol after repeated dosing, ranged from 40 to 52&nbsp;hours which is consistent with the observed time to steady state of approximately 12 to 14&nbsp;days.</p><p>&nbsp;</p><p><em><u>Mometasone furoate</u></em></p><p>After intravenous bolus administration, mometasone furoate has a terminal elimination T<sub>&frac12;</sub> of approximately 4.5&nbsp;hours. A radiolabelled, orally inhaled dose is excreted mainly in the faeces (74%) and to a lesser extent in the urine (8%).</p><p>&nbsp;</p><p><u>Interactions</u></p><p>&nbsp;</p><p>Concomitant administration of orally inhaled indacaterol and mometasone furoate under steady‑state conditions did not affect the pharmacokinetics of either active substance.</p><p>&nbsp;</p><p><u>Linearity/non‑linearity</u></p><p>&nbsp;</p><p>Systemic exposure of mometasone furoate increased in a dose proportional manner following single and multiple doses of Atectura Breezhaler 125&nbsp;mcg/62.5&nbsp;mcg and 125&nbsp;mcg/260&nbsp;mcg in healthy subjects. A less than proportional increase in steady‑state systemic exposure was noted in patients with asthma over the dose range of 125&nbsp;mcg/62.5&nbsp;mcg to 125&nbsp;mcg/260&nbsp;mcg. Dose proportionality assessments were not performed for indacaterol as only one dose was used across all dose strengths.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Atectura Breezhaler may be used in adolescent patients (12&nbsp;years of age and older) at the same posology as in adults.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p>A population pharmacokinetic analysis in patients with asthma after inhalation of indacaterol/mometasone furoate indicated no significant effect of age, gender, body weight, smoking status, baseline estimated glomerular filtration rate (eGFR) and FEV<sub>1</sub> at baseline on the systemic exposure to indacaterol and mometasone furoate.</p><p>&nbsp;</p><p><em><u>Patients with renal impairment</u></em></p><p>Due to the very low contribution of the urinary pathway to total body elimination of indacaterol and mometasone furoate, the effects of renal impairment on their systemic exposure have not been investigated (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em><u>Patients with hepatic impairment</u></em></p><p>The effect of indacaterol/mometasone furoate has not been evaluated in subjects with hepatic impairment. However, studies have been conducted with the monotherapy components (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em>Indacaterol</em></p><p>Patients with mild and moderate hepatic impairment showed no relevant changes in C<sub>max</sub> or AUC of indacaterol, nor did protein binding differ between mild and moderate hepatic impaired subjects and their healthy controls. No data are available for subjects with severe hepatic impairment.</p><p>&nbsp;</p><p><em>Mometasone furoate</em></p><p>A study evaluating the administration of a single inhaled dose of 400&nbsp;mcg mometasone furoate by dry powder inhaler to subjects with mild (n=4), moderate (n=4), and severe (n=4) hepatic impairment resulted in only 1 or 2&nbsp;subjects in each group having detectable peak plasma concentrations of mometasone furoate (ranging from 50 to 105&nbsp;pcg/ml). The observed peak plasma concentrations appear to increase with severity of hepatic impairment; however, the numbers of detectable levels (assay lower limit of quantification was 50&nbsp;pcg/ml) were few.</p><p>&nbsp;</p><p><em><u>Other special populations</u></em></p><p>There were no major differences in total systemic exposure (AUC) for both compounds between Japanese and Caucasian subjects. Insufficient pharmacokinetic data are available for other ethnicities or races.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The non‑clinical assessments of each monotherapy and of the combination product are presented below.</p><p><u>&nbsp;</u></p><p><u>Indacaterol and mometasone furoate combination</u></p><p>&nbsp;</p><p>The findings during the 13‑week inhalation toxicity studies were predominantly attributable to the mometasone furoate component and were typical pharmacological effects of glucocorticoids. Increased heart rates associated with indacaterol were apparent in dogs after administration of indacaterol/mometasone furoate or indacaterol alone.</p><p>&nbsp;</p><p><u>Indacaterol</u></p><p>&nbsp;</p><p>Effects on the cardiovascular system attributable to the beta<sub>2</sub>‑agonistic properties of indacaterol included tachycardia, arrhythmias and myocardial lesions in dogs. Mild irritation of the nasal cavity and larynx was seen in rodents.</p><p>&nbsp;</p><p>Genotoxicity studies did not reveal any mutagenic or clastogenic potential.</p><p>&nbsp;</p><p>Carcinogenicity was assessed in a two‑year rat study and a six‑month transgenic mouse study. Increased incidences of benign ovarian leiomyoma and focal hyperplasia of ovarian smooth muscle in rats were consistent with similar findings reported for other beta<sub>2</sub>‑adrenergic agonists. No evidence of carcinogenicity was seen in mice.</p><p>&nbsp;</p><p>All these findings occurred at exposures sufficiently in excess of those anticipated in humans.</p><p>&nbsp;</p><p>Following subcutaneous administration in a rabbit study, adverse effects of indacaterol with respect to pregnancy and embryonal/foetal development could only be demonstrated at doses more than 500‑fold those achieved following daily inhalation of 150&nbsp;mcg in humans (based on AUC<sub>0‑24&nbsp;h</sub>).</p><p>&nbsp;</p><p>Although indacaterol did not affect general reproductive performance in a rat fertility study, a decrease in the number of pregnant F1 offspring was observed in the peri‑ and post‑natal developmental rat study at an exposure 14‑fold higher than in humans treated with indacaterol. Indacaterol was not embryotoxic or teratogenic in rats or rabbits.</p><p>&nbsp;</p><p><u>Mometasone furoate</u></p><p>&nbsp;</p><p>All observed effects are typical of the glucocorticoid class of compounds and are related to exaggerated pharmacological effects of glucocorticoids. Mometasone furoate showed no genotoxic activity in a standard battery of <em>in vitro</em> and <em>in vivo</em> tests.</p><p>&nbsp;</p><p>In carcinogenicity studies in mice and rats, inhaled mometasone furoate demonstrated no statistically significant increase in the incidence of tumours.</p><p>&nbsp;</p><p>Like other glucocorticoids, mometasone furoate is a teratogen in rodents and rabbits. Effects noted were umbilical hernia in rats, cleft palate in mice and gallbladder agenesis, umbilical hernia and flexed front paws in rabbits. There were also reductions in maternal body weight gains, effects on foetal growth (lower foetal body weight and/or delayed ossification) in rats, rabbits and mice, and reduced offspring survival in mice. In studies of reproductive function, subcutaneous mometasone furoate at 15&nbsp;mcg/kg prolonged gestation and difficult labour occurred, with a reduction in offspring survival and body weight.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u></p><p>&nbsp;</p><p>Lactose monohydrate</p><p>&nbsp;</p><p><u>Capsule shell</u></p><p>&nbsp;</p><p>Gelatin</p><p>Printing ink</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from light and moisture.</p><p>This medicinal product does not require any special temperature storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inhaler body and cap are made from acrylonitrile butadiene styrene, push buttons are made from methyl metacrylate acrylonitrile butadiene styrene. Needles and springs are made from stainless steel.</p><p>&nbsp;</p><p>PA/Alu/PVC &ndash; Alu perforated unit‑dose blister. Each blister contains 10&nbsp;hard capsules.</p><p>&nbsp;</p><p><u>Atectura Breezhaler 125&nbsp;micrograms/62.5&nbsp;micrograms inhalation powder, hard capsules</u></p><p>&nbsp;</p><p>Single pack containing 10&nbsp;x&nbsp;1 or 30&nbsp;x&nbsp;1&nbsp;hard capsules, together with 1&nbsp;inhaler.</p><p>Multipacks containing 90&nbsp;(3&nbsp;packs of 30&nbsp;x&nbsp;1)&nbsp;hard capsules and 3&nbsp;inhalers.</p><p>Multipacks containing 150&nbsp;(15&nbsp;packs of 10&nbsp;x&nbsp;1)&nbsp;hard capsules and 15&nbsp;inhalers.</p><p>&nbsp;</p><p><u>Atectura Breezhaler 125&nbsp;micrograms/127.5&nbsp;micrograms inhalation powder, hard capsules</u></p><p>&nbsp;</p><p>Single pack containing 10&nbsp;x&nbsp;1 or 30&nbsp;x&nbsp;1&nbsp;hard capsules, together with 1&nbsp;inhaler.</p><p>Multipacks containing 90&nbsp;(3&nbsp;packs of 30&nbsp;x&nbsp;1)&nbsp;hard capsules and 3&nbsp;inhalers.</p><p>Multipacks containing 150&nbsp;(15&nbsp;packs of 10&nbsp;x&nbsp;1)&nbsp;hard capsules and 15&nbsp;inhalers.</p><p>&nbsp;</p><p><u>Atectura Breezhaler 125&nbsp;micrograms/260&nbsp;micrograms inhalation powder, hard capsules</u></p><p>&nbsp;</p><p>Single pack containing 10&nbsp;x&nbsp;1 or 30&nbsp;x&nbsp;1&nbsp;hard capsules, together with 1&nbsp;inhaler.</p><p>Multipacks containing 90&nbsp;(3&nbsp;packs of 30&nbsp;x&nbsp;1)&nbsp;hard capsules and 3&nbsp;inhalers.</p><p>Multipacks containing 150&nbsp;(15&nbsp;packs of 10&nbsp;x&nbsp;1)&nbsp;hard capsules and 15&nbsp;inhalers.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The inhaler provided with each new prescription should be used. The inhaler in each pack should be disposed of after all capsules in that pack have been used.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><u>Instructions for handling and use</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p>Please read the full <strong>Instructions for Use</strong> before using the Atectura Breezhaler.</p><p>&nbsp;</p></td></tr><tr><td><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
   coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
   filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_18" o:spid="_x0000_i1042" type="#_x0000_t75"
   style='width:108pt;height:79.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
  </v:shape><![endif]--><img width="144" height="106" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_17"
   o:spid="_x0000_i1041" type="#_x0000_t75" style='width:115.5pt;height:87.75pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png"
    o:title=""/>
  </v:shape><![endif]--><img width="154" height="117" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.jpg" /></p></td><td><p><!--[if gte vml 1]><v:shape id="Picture_x0020_16"
   o:spid="_x0000_i1040" type="#_x0000_t75" style='width:102.75pt;height:82.5pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png"
    o:title=""/>
  </v:shape><![endif]--><img width="137" height="110" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.jpg" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_15"
   o:spid="_x0000_i1039" type="#_x0000_t75" style='width:86.25pt;height:98.25pt;
   visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.png"
    o:title=""/>
  </v:shape><![endif]--><img width="115" height="131" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image008.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p><strong>Insert</strong></p></td><td style="vertical-align:top"><p><strong>Pierce and release</strong></p></td><td style="vertical-align:top"><p><strong>Inhale deeply</strong></p></td><td style="vertical-align:top"><p><strong>Check capsule is empty</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shapetype id="_x0000_t67"
   coordsize="21600,21600" o:spt="67" adj="16200,5400" path="m0@0l@1@0@1,0@2,0@2@0,21600@0,10800,21600xe">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="val #0"/>
    <v:f eqn="val #1"/>
    <v:f eqn="sum height 0 #1"/>
    <v:f eqn="sum 10800 0 #1"/>
    <v:f eqn="sum width 0 #0"/>
    <v:f eqn="prod @4 @3 10800"/>
    <v:f eqn="sum width 0 @5"/>
   </v:formulas>
   <v:path o:connecttype="custom" o:connectlocs="10800,0;0,@0;10800,21600;21600,@0"
    o:connectangles="270,180,90,0" textboxrect="@1,0,@2,@6"/>
   <v:handles>
    <v:h position="#1,#0" xrange="0,10800" yrange="0,21600"/>
   </v:handles>
  </v:shapetype><v:shape id="Down_x0020_Arrow_x0020_64" o:spid="_x0000_s1041"
   type="#_x0000_t67" style='position:absolute;margin-left:7.65pt;margin-top:7.35pt;
   width:100.5pt;height:67.15pt;z-index:251650048;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAVSJFrrYDAAAYDAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsVttuGzcQfS/QfyD4nmh1jSJkHch2
ZRRQHcNykGeKy5UW5ZIsSd3yNf2WflkPyV1p4xop0MtDi8iwNOTMDmfOnBnuu/fHWpK9sK7SKqf9
1xklQnFdVGqT049Pi1dTSpxnqmBSK5HTk3D0/dX3371js41lZltxAg/KzVhOt96bWa/n+FbUzL3W
RijoSm1r5rG0m15h2QGea9kbZNmkV7NK0auLq1vmGdnZ6i+4kpr/LIobpvbMwaXks+5OE6Pkf98z
m6n9nTUr82BD5Px+/2BJVeQUyClWAyLaaxSNGZa9Z09tLg6Opa2DvS5LckQFsmnWH44pOeV0NB2O
x4Nx8ieOnvBgMHgzGY5xGIfFdDyYZo0B3374Exd8+8PXnSDMFA6ETojOhADV/o85T0Zt0rf6oMjc
Wn0g2GwRaJ9wZon6uIQEIEv7EZWLSQL0H8LjnAqbGev8ndA1CUJOC0QaA43MY/ul8ymu1i4k67Ss
ikUlZVyc3I20ZM9kTkFfOKBEMuexmdNF/ERfclf/pItkN87wCTggEBefT2LXr1TkEAsKS8KZyWkp
mYdYG/DJqQ0lTG7QltzbeIDSIaQIbgj2lrltOi2Gm1CvKy8skVUNdoQY2iCkCqmIshTcn1N2DYv9
cRVr7I/XujgFwzV+QWyrgRiic4YvKhy5RNoPzKLZsYmx4T/gq5QaeehGomSr7eeX9oM9GhBaSg4Y
Hsjxlx2zAmj+qFxO3/ZHI7j1cTEavxlgYbuadVejdvWNRkX6MbooBnsvW7G0uv6kbTEPp0LFFMfZ
Cc1mceOxhgoziov5PMpc14b5pVoZTIt+xD2A/XT8xKxpOOTRjfd6tWVGvMSiZBtgVHq+87qsGool
VINCOr/yJylSMcMOSkFqZpcxCAiPKegvCCBDVMEY9XjwLhW/P+wU+aK/FuVzy5YLePqinZf+K3aN
1rM1SBPsIBGjUa3hJMtGGFSJorLhemsI2jfcsuEpi+QkC3eKUK/urlGyzwB3FIi/blGOJD73nN2s
z03X9FjTTd0W6vIZoDJfKeJPRpSMYxI/VbVw5F4cyKOumaLEMKUdFNkAf5NsmI2zEf4HkDDJTOX5
dsHqSmK09nHx8S2zTkT2xDoJ9q85B17AKAJ81Q9DA2CHvbAjVBF67rGL4cdVg2EfGEajTmf/15G4
JBxBiKMpfb3UIyH7b43x7M76XzbGb79+64x2FLSdEUbF+dbeObEyj7jh06hM1zoswhtc79k7cXTQ
vMOHF+/u+up3AAAA//8DAFBLAwQUAAYACAAAACEAkS1qSVgGAAAPGgAAGgAAAGNsaXBib2FyZC90
aGVtZS90aGVtZTEueG1s7FlLbxs3EL4X6H9Y7L2x3oqNyIGtR9zEToJISZEjpaV2GXOXC5Kyo1uR
nHopUCAtemiA3nooigZogAa99McYcNCmP6JD7kOkRMUPuEBQxAKM3dlvhsOZ2W9I7o2bT2PqHWEu
CEs6fvVaxfdwMmEBScKO/3A0+Oy67wmJkgBRluCOP8fCv7n96Sc30NaEknTMEA9GEY6xB4YSsYU6
fiRlurWxISYgRuIaS3ECz6aMx0jCLQ83Ao6OYYCYbtQqldZGjEjib4NFqQz1KfxLpFCCCeVDZQZ7
CYph9HvTKZlgjQ0Oqwoh5qJLuXeEaMcHmwE7HuGn0vcoEhIedPyK/vM3tm9soK1cico1uobeQP/l
erlCcFjTY/JwXA7aaDQbrZ3SvgZQuYrrt/utfqu0pwFoMoGZZr6YNpu7m7u9Zo41QNmlw3av3atX
Lbxhv77i805T/Sy8BmX2Gyv4waALUbTwGpThmyv4RqNd6zYsvAZl+NYKvl3Z6TXaFl6DIkqSwxV0
pdmqd4vZlpApo3tO+GazMWjXcuMLFFRDWV1qiClL5Lpai9ETxgcAUECKJEk8OU/xFE2gJruIkjEn
3j4JIyi8FCVMgLhSqwwqdfivfg19pSOCtjAytJVf4IlYESl/PDHhJJUd/zZY9Q3I6Zs3J89enzz7
/eT585Nnv+Zja1OW3h5KQlPv3U/f/PPyS+/v33589+LbbOhlvDDxb3/56u0ff77PPMx4EYrT7169
ff3q9Puv//r5hcP6DkdjEz4iMRbeXXzsPWAxTNDhPx7zi2mMIkRMjZ0kFChBahSH/b6MLPTdOaLI
gdvFdhwfcaAaF/DW7Inl8DDiM0kcFu9EsQU8YIzuMu6Mwh01lhHm0SwJ3YPzmYl7gNCRa+wuSqws
92cpcCxxmexG2HLzPkWJRCFOsPTUM3aIsWN2jwmx4npAJpwJNpXeY+LtIuIMyYiMrWpaKO2RGPIy
dzkI+bZic/DI22XUNesePrKR8G4g6nB+hKkVxltoJlHsMjlCMTUDvo9k5HJyOOcTE9cXEjIdYsq8
foCFcOnc4zBfI+l3gGbcaT+g89hGckkOXTb3EWMmsscOuxGKUxd2SJLIxH4uDqFEkXefSRf8gNlv
iLqHPKBkbbofEWyl+2w2eAgMa7q0KBD1ZMYdubyFmVW/wzmdIqypBhqAxesxSc4k+SV6b/539A4k
evrDS8eMrobS3YatfFyQzHc4cb5Ne0sUvg63TNxdxgPy4fN2D82S+xheldXm9ZG2P9K2/7+n7XXv
89WT9YKfgbrVsjVbruvFe7x27T4llA7lnOJ9oZfvArpSMACh0tN7VFzu5dIILtWbDANYuJAjreNx
Jr8gMhpGKIU1ftVXRkKRmw6FlzIBS38tdtpWeDqLD1iQbVmrVbU9zchDILmQV5qlHLYbMkO32ott
WGleexvq7XLhgNK9iBPGYLYTdYcT7UKogqQ35xA0hxN6ZlfixabDi+vKfJGqFS/AtTIrsGzyYLHV
8ZsNUAEl2FUhigOVpyzVRXZ1Mq8y0+uCaVUArCGKClhkelP5unZ6anZZqZ0j05YTRrnZTujI6B4m
IhTgvDqV9DxuXDTXm4uUWu6pUOjxoLQWbrSvv8+Ly+Ya9Ja5gSYmU9DEO+74rXoTSmaC0o4/ha0/
XMYp1I5Qy11EQzg0m0ievfCXYZaUC9lDIsoCrkknY4OYSMw9SuKOr6ZfpoEmmkO0b9UaEMIH69wm
0MqH5hwk3U4ynk7xRJppNyQq0tktMHzGFc6nWv3yYKXJZpDuYRQce2M64w8QlFizXVUBDIiAE6Bq
Fs2AwJFmSWSL+ltqTDntmmeKuoYyOaJphPKOYpJ5BtdUXrqj78oYGHf5nCGgRkjyRjgOVYM1g2p1
07JrZD6s7bpnK6nIGaS56JkWq6iu6WYxa4SiDSzF8nJN3vCqCDFwmtnhM+peptzNguuW1glll4CA
l/FzdN1zNATDtcVglmvK41UaVpydS+3eUUzwDNfO0yQM1m8VZpfiVvYI53AgvFTnB73lqgXRtFhX
6ki7Pk8coNQbh9WOD58I4GziKVzBRwYfZDUlqykZXMGXA2gX2XF/x88vCgk8zyQlpl5I6gWmUUga
haRZSJqFpFVIWr6nz8XhW4w6Eve94tgbelh+TJ6vLexvONv/AgAA//8DAFBLAwQUAAYACAAAACEA
nGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVs
c4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN+7IzeWJMk3cc
aloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOP
VuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwGMwdKV2ed
NS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAA
AAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBVIkWutgMAABgMAAAfAAAA
AAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgA
AAAhAJEtaklYBgAADxoAABoAAAAAAAAAAAAAAAAAEwYAAGNsaXBib2FyZC90aGVtZS90aGVtZTEu
eG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAAowwAAGNsaXBib2Fy
ZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcBAACmDQAAAAA=
" adj="10800" fillcolor="#7f7f7f" stroked="f" strokeweight="1pt">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:
      14.0pt;mso-bidi-font-size:10.0pt;color:white'>1<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      lang=EN-GB style='font-size:14.0pt;mso-bidi-font-size:10.0pt;color:white'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="139" height="95" alt="Arrow: Down: 1

" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image009.png" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Down_x0020_Arrow_x0020_236"
   o:spid="_x0000_s1040" type="#_x0000_t67" style='position:absolute;
   margin-left:2.2pt;margin-top:7.35pt;width:104.9pt;height:64.9pt;z-index:251651072;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" adj="10800" fillcolor="#7f7f7f" stroked="f" strokeweight="1pt">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:
      14.0pt;mso-bidi-font-size:10.0pt;color:white'>2<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      lang=EN-GB style='font-size:14.0pt;mso-bidi-font-size:10.0pt;color:white'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="145" height="92" alt="Arrow: Down: 2

" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image010.png" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Down_x0020_Arrow_x0020_237"
   o:spid="_x0000_s1039" type="#_x0000_t67" style='position:absolute;
   margin-left:3pt;margin-top:7.35pt;width:99.75pt;height:67.85pt;z-index:251652096;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" adj="10800" fillcolor="#7f7f7f" stroked="f" strokeweight="1pt">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:
      14.0pt;mso-bidi-font-size:10.0pt;color:white'>3<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      lang=EN-GB style='font-size:14.0pt;mso-bidi-font-size:10.0pt;color:white'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="138" height="96" alt="Arrow: Down: 3

" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image011.png" /></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Down_x0020_Arrow_x0020_238"
   o:spid="_x0000_s1038" type="#_x0000_t67" style='position:absolute;
   margin-left:.3pt;margin-top:7.35pt;width:111.05pt;height:63.95pt;z-index:251653120;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAL54OcucDAABvDAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsV9tuGzcQfS/QfyD4nmhXN9tC1oEs
V0YBxzEsB3mmuVztNrxsSeqWr+m39Mt6SK6sjRu0QC8PLSLD8pAzO5w5M2e4fvN2ryTZCusaowua
v84oEZqbstHrgn54XL46p8R5pksmjRYFPQhH315+/90bNltb1tYNJ/Cg3YwVtPa+nQ0GjtdCMffa
tEJDVxmrmMfSrgelZTt4VnIwzLLpQLFG08uTq2vmGdnY5i+4koZ/EuWC6S1zcCn5rL/TxSj53/fM
Znp7Y9tVe29D5Pxue29JUxYUyGmmABEddIrODMvBi6fWJwf7yqpgb6qK7As6GZ1NLnL4OhR0fD6a
TIaT5E/sPeEwyMd5NhpNKOGwOM+H+bQz4PX7P3HB6x/+2AnCTOFA6IXo2hCg3v4+5+EI7ZGyvjY7
TebWmh0Ju0cMjs+49hYVcgkLgJb2Iy4nkwTpP4TIczJs1lrnb4RRJAgFLRFqjDT2HtveOh8SXJdd
Kqz8KaekUhI9vWWSTDJ8UkZ9m2HfZjy9mF4EGxzbeYR0PDi4d0Y25bKRMi4ObiEtgfeCghGIiBLJ
nMdmQZfxE4OTG/XOlMnuOQw4dvH5eNoXfqUmO/TI8AwBE87aglaSeYiqRYs6vaaEyTWYzr2NB2gT
QorVCsFeM1en06LblLRqvLBENgoNF6CIWCAIqUMqoqoE98AwJe86Yvj9KraN31+Z8hAMn/AXXLEG
JUB0ruXLBkfeIu17ZoE1NjGJ/Ht8VdIgD9NJlNTGfv7afrAHp6GlZId5hBx/3jArgOaP2hX0Ih+P
4dbHxXhyNsTC9jVPfY3eqIVBRVB9RBfFYO/lUaysUR+NLefhVKiY5jg7odktFh5rqDD2uJjPo8yN
apm/1asWAyiPuAewH/cfmW27pvQg+J1Z1awVp7ZMkJ5sA4zazDfeVE2Hd0I1KKTzK3+QIhUz7KAU
RDF7G4OA8JCC/qIBZIgqGCPje+9S8fNRr8gn/ZWoXloeewFPn7TzKhKq77Fn12k9e+qIB4m0BtUa
TbNsjNGWWlR2dDoaBj6lCWFDFBbJSRauKaFf3VyhZJ/DdAyN/3REOTbxM+fs+umZdB3Hup7tU7Pf
zwCV+UYTf2hFxTiG+2OjhCN3YkcejGKakpZp46DIhviZZqNsko3xO4Q0hrbxvF4y1UhM6xzDktfM
OhG7J9ZJsH/NOfACRgEqf7moBf8UZhMKE/bDrtBl4N1DH8cPqw7HHDhGox67/+tonBKOIMTxlL6+
xpOQ/TdyvLi3/pfk+PWXb8w4joIjM8KoeL65N06s2gfc8mlcpqsdFuHFcPDiVTs66P41CO/z/fXl
bwAAAP//AwBQSwMEFAAGAAgAAAAhAJEtaklYBgAADxoAABoAAABjbGlwYm9hcmQvdGhlbWUvdGhl
bWUxLnhtbOxZS28bNxC+F+h/WOy9sd6KjciBrUfcxE6CSEmRI6WldhlzlwuSsqNbkZx6KVAgLXpo
gN56KIoGaIAGvfTHGHDQpj+iQ+5DpETFD7hAUMQCjN3Zb4bDmdlvSO6Nm09j6h1hLghLOn71WsX3
cDJhAUnCjv9wNPjsuu8JiZIAUZbgjj/Hwr+5/eknN9DWhJJ0zBAPRhGOsQeGErGFOn4kZbq1sSEm
IEbiGktxAs+mjMdIwi0PNwKOjmGAmG7UKpXWRoxI4m+DRakM9Sn8S6RQggnlQ2UGewmKYfR70ymZ
YI0NDqsKIeaiS7l3hGjHB5sBOx7hp9L3KBISHnT8iv7zN7ZvbKCtXInKNbqG3kD/5Xq5QnBY02Py
cFwO2mg0G62d0r4GULmK67f7rX6rtKcBaDKBmWa+mDabu5u7vWaONUDZpcN2r92rVy28Yb++4vNO
U/0svAZl9hsr+MGgC1G08BqU4Zsr+EajXes2LLwGZfjWCr5d2ek12hZegyJKksMVdKXZqneL2ZaQ
KaN7TvhmszFo13LjCxRUQ1ldaogpS+S6WovRE8YHAFBAiiRJPDlP8RRNoCa7iJIxJ94+CSMovBQl
TIC4UqsMKnX4r34NfaUjgrYwMrSVX+CJWBEpfzwx4SSVHf82WPUNyOmbNyfPXp88+/3k+fOTZ7/m
Y2tTlt4eSkJT791P3/zz8kvv799+fPfi22zoZbww8W9/+ertH3++zzzMeBGK0+9evX396vT7r//6
+YXD+g5HYxM+IjEW3l187D1gMUzQ4T8e84tpjCJETI2dJBQoQWoUh/2+jCz03TmiyIHbxXYcH3Gg
Ghfw1uyJ5fAw4jNJHBbvRLEFPGCM7jLujMIdNZYR5tEsCd2D85mJe4DQkWvsLkqsLPdnKXAscZns
Rthy8z5FiUQhTrD01DN2iLFjdo8JseJ6QCacCTaV3mPi7SLiDMmIjK1qWijtkRjyMnc5CPm2YnPw
yNtl1DXrHj6ykfBuIOpwfoSpFcZbaCZR7DI5QjE1A76PZORycjjnExPXFxIyHWLKvH6AhXDp3OMw
XyPpd4Bm3Gk/oPPYRnJJDl029xFjJrLHDrsRilMXdkiSyMR+Lg6hRJF3n0kX/IDZb4i6hzygZG26
HxFspftsNngIDGu6tCgQ9WTGHbm8hZlVv8M5nSKsqQYagMXrMUnOJPklem/+d/QOJHr6w0vHjK6G
0t2GrXxckMx3OHG+TXtLFL4Ot0zcXcYD8uHzdg/NkvsYXpXV5vWRtj/Stv+/p+117/PVk/WCn4G6
1bI1W67rxXu8du0+JZQO5ZzifaGX7wK6UjAAodLTe1Rc7uXSCC7VmwwDWLiQI63jcSa/IDIaRiiF
NX7VV0ZCkZsOhZcyAUt/LXbaVng6iw9YkG1Zq1W1Pc3IQyC5kFeapRy2GzJDt9qLbVhpXnsb6u1y
4YDSvYgTxmC2E3WHE+1CqIKkN+cQNIcTemZX4sWmw4vrynyRqhUvwLUyK7Bs8mCx1fGbDVABJdhV
IYoDlacs1UV2dTKvMtPrgmlVAKwhigpYZHpT+bp2emp2WamdI9OWE0a52U7oyOgeJiIU4Lw6lfQ8
blw015uLlFruqVDo8aC0Fm60r7/Pi8vmGvSWuYEmJlPQxDvu+K16E0pmgtKOP4WtP1zGKdSOUMtd
REM4NJtInr3wl2GWlAvZQyLKAq5JJ2ODmEjMPUrijq+mX6aBJppDtG/VGhDCB+vcJtDKh+YcJN1O
Mp5O8USaaTckKtLZLTB8xhXOp1r98mClyWaQ7mEUHHtjOuMPEJRYs11VAQyIgBOgahbNgMCRZklk
i/pbakw57ZpnirqGMjmiaYTyjmKSeQbXVF66o+/KGBh3+ZwhoEZI8kY4DlWDNYNqddOya2Q+rO26
ZyupyBmkueiZFquorulmMWuEog0sxfJyTd7wqggxcJrZ4TPqXqbczYLrltYJZZeAgJfxc3TdczQE
w7XFYJZryuNVGlacnUvt3lFM8AzXztMkDNZvFWaX4lb2COdwILxU5we95aoF0bRYV+pIuz5PHKDU
G4fVjg+fCOBs4ilcwUcGH2Q1JaspGVzBlwNoF9lxf8fPLwoJPM8kJaZeSOoFplFIGoWkWUiahaRV
SFq+p8/F4VuMOhL3veLYG3pYfkyery3sbzjb/wIAAP//AwBQSwMEFAAGAAgAAAAhAJxmRkG7AAAA
JAEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHOEj80KwjAQ
hO+C7xD2btJ6EJEmvYjQq9QHCMk2LTY/JFHs2xvoRUHwsjCz7DezTfuyM3liTJN3HGpaAUGnvJ6c
4XDrL7sjkJSl03L2DjksmKAV201zxVnmcpTGKSRSKC5xGHMOJ8aSGtHKRH1AVzaDj1bmIqNhQaq7
NMj2VXVg8ZMB4otJOs0hdroG0i+hJP9n+2GYFJ69elh0+UcEy6UXFqCMBjMHSldnnTUtXYGJhn39
Jt4AAAD//wMAUEsBAi0AFAAGAAgAAAAhALvlSJQFAQAAHgIAABMAAAAAAAAAAAAAAAAAAAAAAFtD
b250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAAAAAAAAAAAA
AAA2AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAL54OcucDAABvDAAAHwAAAAAAAAAAAAAA
AAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBLAQItABQABgAIAAAAIQCRLWpJ
WAYAAA8aAAAaAAAAAAAAAAAAAAAAAEQGAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbFBLAQIt
ABQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAAAAAAAAAAAAAANQMAABjbGlwYm9hcmQvZHJhd2lu
Z3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQSwUGAAAAAAUABQBnAQAA1w0AAAAA
" adj="11455" fillcolor="#7f7f7f" stroked="f" strokeweight="1pt">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:
      14.0pt;color:white'>Check<o:p></o:p></span></b></p>
      <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
      lang=EN-GB style='font-size:14.0pt;color:white'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><![endif]--><img width="153" height="90" alt="Arrow: Down: Check

" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image012.png" /></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_14" o:spid="_x0000_i1038"
   type="#_x0000_t75" style='width:76.5pt;height:96.75pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image013.png"
    o:title=""/>
  </v:shape><![endif]--><img width="102" height="129" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image014.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_13" o:spid="_x0000_i1037"
   type="#_x0000_t75" style='width:102.75pt;height:89.25pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image015.png"
    o:title=""/>
  </v:shape><![endif]--><img width="137" height="119" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image016.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_12" o:spid="_x0000_i1036"
   type="#_x0000_t75" style='width:102.75pt;height:62.25pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image017.png"
    o:title=""/>
  </v:shape><![endif]--><img width="137" height="83" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image018.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Picture_x0020_11" o:spid="_x0000_i1035"
   type="#_x0000_t75" style='width:86.25pt;height:98.25pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.png"
    o:title=""/>
  </v:shape><![endif]--><img width="115" height="131" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image019.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>Step&nbsp;1a:</p><p><strong>Pull off cap</strong></p></td><td style="vertical-align:top"><p>Step&nbsp;2a:</p><p><strong>Pierce capsule once</strong></p><p>Hold the inhaler upright.</p><p>Pierce capsule by firmly pressing both side buttons at the same time.</p></td><td style="vertical-align:top"><p>Step&nbsp;3a:</p><p><strong>Breathe out fully</strong></p><p><u>Do not blow into the inhaler.</u></p></td><td style="vertical-align:top"><p><strong>Check capsule is empty</strong></p><p>Open the inhaler to see if any powder is left in the capsule.</p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_10" o:spid="_x0000_i1034" type="#_x0000_t75" style='width:97.5pt;
   height:88.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image020.png"
    o:title=""/>
  </v:shape><![endif]--><img width="130" height="118" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image021.jpg" /></p></td><td style="vertical-align:top"><p>You should hear a<strong> </strong>noise<strong> </strong>as the capsule is pierced.</p><p><u>Only pierce the capsule once.</u></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_9" o:spid="_x0000_i1033" type="#_x0000_t75" style='width:102.75pt;
   height:67.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image022.png"
    o:title=""/>
  </v:shape><![endif]--><img width="137" height="90" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image023.jpg" /></p></td><td style="vertical-align:top"><p>If there is powder left in the capsule:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Close the inhaler.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeat steps&nbsp;3a to 3d.</p></td></tr><tr><td style="vertical-align:top"><p>Step&nbsp;1b:</p><p><strong>Open inhaler</strong></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_8" o:spid="_x0000_i1032" type="#_x0000_t75" style='width:102.75pt;
   height:93.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image024.png"
    o:title=""/>
  </v:shape><![endif]--><img width="137" height="125" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image025.jpg" /></p><p>Step&nbsp;2b:</p><p><strong>Release side buttons</strong></p></td><td style="vertical-align:top"><p>Step&nbsp;3b:</p><p><strong>Inhale medicine deeply</strong></p><p>Hold the inhaler as shown in the picture.</p><p>Place the mouthpiece in your mouth and close your lips firmly around it.</p><p><u>Do not press the side buttons</u>.</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_7" o:spid="_x0000_i1031"
   type="#_x0000_t75" style='width:110.25pt;height:25.5pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image026.png"
    o:title=""/>
  </v:shape><![endif]--><img width="147" height="34" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image027.jpg" /></p><p><strong>Powder&nbsp; Empty</strong></p><p><strong>remaining</strong></p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><o:wrapblock><v:shape id="Picture_x0020_19" o:spid="_x0000_s1037"
    type="#_x0000_t75" style='position:absolute;left:0;text-align:left;
    margin-left:-.55pt;margin-top:10.1pt;width:108pt;height:79.5pt;z-index:251654144;
    visibility:visible;mso-wrap-style:square;mso-width-percent:0;
    mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
    mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
    mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
    mso-position-vertical:absolute;mso-position-vertical-relative:text;
    mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
    mso-height-relative:page'>
    <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image028.png"
     o:title="" cropbottom="28585f"/>
    <w:wrap type="topAndBottom"/>
   </v:shape><![endif]--><img width="144" height="106" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image029.jpg" /><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><!--[if gte vml 1]><v:shape
   id="Picture_x0020_6" o:spid="_x0000_i1030" type="#_x0000_t75" style='width:108pt;
   height:66.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image030.png"
    o:title=""/>
  </v:shape><![endif]--><img width="144" height="89" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image031.jpg" /></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Breathe in quickly and as deeply as you can.</p><p>During inhalation you will hear a whirring noise.</p><p>You may taste the medicine as you inhale.</p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_5" o:spid="_x0000_i1029" type="#_x0000_t75" style='width:105.75pt;
   height:138.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image032.png"
    o:title=""/>
  </v:shape><![endif]--><img width="141" height="185" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image033.jpg" /></p></td></tr><tr><td style="vertical-align:top"><p>Step&nbsp;1c:</p><p><strong>Remove capsule</strong></p><p>Separate one of the blisters from the blister card.</p><p>Peel open the blister and remove the capsule.</p><p><u>Do not push the capsule through the foil.</u></p><p><u>Do not swallow the capsule.</u></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_4" o:spid="_x0000_i1028" type="#_x0000_t75" style='width:102.75pt;
   height:73.5pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image034.png"
    o:title=""/>
  </v:shape><![endif]--><img width="137" height="98" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image035.jpg" /></p><p>Step&nbsp;3c:</p><p><strong>Hold breath</strong></p><p>Hold your breath for up to 5&nbsp;seconds.</p><p>&nbsp;</p><p>&nbsp;</p><p>Step&nbsp;3d:</p><p><strong>Rinse mouth</strong></p><p>Rinse your mouth with water after each dose and spit it out.</p></td><td style="vertical-align:top"><p><strong>Remove empty capsule</strong></p><p>Put the empty capsule in your household waste.</p><p>&nbsp;</p><p>Close the inhaler and replace the cap.</p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape
   id="Picture_x0020_3" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:105.75pt;
   height:69pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image036.png"
    o:title=""/>
  </v:shape><![endif]--><img width="141" height="92" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image037.jpg" /></p><p>Step&nbsp;1d:</p><p><strong>Insert capsule</strong></p><p><u>Never place a capsule directly into the mouthpiece.</u></p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Important Information</strong></p><p>&middot;&nbsp;&nbsp; Atectura Breezhaler<strong> </strong>capsules must always be stored in the blister card and only removed immediately before use.</p><p>&middot;&nbsp;&nbsp; Do not push the capsule through the foil to remove it from the blister.</p><p>&middot;&nbsp;&nbsp; Do not swallow the capsule.</p><p>&middot;&nbsp;&nbsp; Do not use the Atectura Breezhaler capsules with any other inhaler.</p><p>&middot;&nbsp;&nbsp; Do not use the Atectura Breezhaler<strong> </strong>inhaler to take any other capsule medicine.</p><p>&middot;&nbsp;&nbsp; Never place the capsule into your mouth or the mouthpiece of the inhaler.</p><p>&middot;&nbsp;&nbsp; Do not press the side buttons more than once.</p><p>&middot;&nbsp;&nbsp; Do not blow into the mouthpiece.</p><p>&middot;&nbsp;&nbsp; Do not press the side buttons while inhaling through the mouthpiece.</p><p>&middot;&nbsp;&nbsp; Do not handle capsules with wet hands.</p><p>&middot;&nbsp;&nbsp; Never wash your inhaler with water.</p></td></tr><tr><td style="vertical-align:top"><p><!--[if gte vml 1]><v:shape id="Picture_x0020_2" o:spid="_x0000_i1026"
   type="#_x0000_t75" style='width:104.25pt;height:96pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image038.png"
    o:title=""/>
  </v:shape><![endif]--><img width="139" height="128" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image039.jpg" /></p><p>Step&nbsp;1e:</p><p><strong>Close inhaler</strong></p></td></tr></tbody></table><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_46" o:spid="_x0000_s1036"
 type="#_x0000_t202" style='position:absolute;margin-left:122pt;margin-top:373.15pt;
 width:48.35pt;height:19.15pt;z-index:251655168;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Mouthpiece</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Your Atectura Breezhaler Inhaler pack contains:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One Atectura Breezhaler inhaler</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:shape
   id="Text_x0020_Box_x0020_45" o:spid="_x0000_s1035" type="#_x0000_t202"
   style='position:absolute;left:0;text-align:left;margin-left:67.9pt;
   margin-top:34.9pt;width:41.6pt;height:30.05pt;text-indent:0;z-index:251656192;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Capsule chamber</p></td></tr></tbody></table></td></tr></tbody></table><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_217"
   o:spid="_x0000_s1034" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:100.4pt;margin-top:30.65pt;width:47.7pt;
   height:20.75pt;text-indent:0;z-index:251657216;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f"/><![endif]--><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Mouthpiece</p></td></tr></tbody></table></td></tr></tbody></table>One or more blister cards, each containing 10&nbsp;Atectura Breezhaler capsules to be used in the inhaler<p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_43"
   o:spid="_x0000_s1033" type="#_x0000_t202" style='position:absolute;left:0;
   text-align:left;margin-left:34.05pt;margin-top:10.75pt;width:30.75pt;
   height:19.15pt;text-indent:0;z-index:251658240;visibility:visible;
   mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
   mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" filled="f" stroked="f"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Cap</p></td></tr></tbody></table></td></tr></tbody></table> &nbsp;<p>&nbsp;</p>&nbsp;<p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_41"
   o:spid="_x0000_s1032" type="#_x0000_t202" style='position:absolute;
   margin-left:27.75pt;margin-top:35.8pt;width:30.75pt;height:19.15pt;
   z-index:251659264;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" filled="f" stroked="f"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Base</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_42"
   o:spid="_x0000_s1031" type="#_x0000_t202" style='position:absolute;
   margin-left:52.3pt;margin-top:25.05pt;width:38.25pt;height:32.15pt;
   z-index:251660288;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f"/><![endif]--><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Side buttons</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_44"
   o:spid="_x0000_s1030" type="#_x0000_t202" style='position:absolute;
   margin-left:118.05pt;margin-top:10.2pt;width:36.75pt;height:18.7pt;
   z-index:251661312;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f"/><![endif]--><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Screen</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_40"
   o:spid="_x0000_s1029" type="#_x0000_t202" style='position:absolute;
   margin-left:151.5pt;margin-top:34.4pt;width:33.75pt;height:18.85pt;
   z-index:251662336;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f"/><![endif]--><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Blister</p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_39"
   o:spid="_x0000_s1028" type="#_x0000_t202" style='position:absolute;
   margin-left:70.7pt;margin-top:62.55pt;width:51.4pt;height:19.15pt;z-index:251663360;
   visibility:visible;mso-wrap-style:square;mso-width-percent:0;
   mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
   mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
   mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
   mso-position-vertical:absolute;mso-position-vertical-relative:text;
   mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
   mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f"/><![endif]--><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Inhaler base</strong></p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_38"
   o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
   margin-left:155.85pt;margin-top:62.9pt;width:54.05pt;height:19.15pt;
   z-index:251664384;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f"/><![endif]--><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Blister card</strong></p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_37"
   o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
   margin-left:1.55pt;margin-top:62.75pt;width:37.15pt;height:19.15pt;
   z-index:251665408;visibility:visible;mso-wrap-style:square;
   mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
   mso-wrap-distance-top:3.6pt;mso-wrap-distance-right:9pt;
   mso-wrap-distance-bottom:3.6pt;mso-position-horizontal:absolute;
   mso-position-horizontal-relative:text;mso-position-vertical:absolute;
   mso-position-vertical-relative:text;mso-width-percent:0;
   mso-height-percent:0;mso-width-relative:margin;mso-height-relative:margin;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f"/><![endif]--><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Inhaler</strong></p></td></tr></tbody></table></td></tr></tbody></table> <!--[if gte vml 1]><v:shape
   id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:214.5pt;
   height:50.25pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image040.png"
    o:title=""/>
  </v:shape><![endif]--><img width="286" height="67" src="file:///C:/Users/alghasu1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image041.jpg" /><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Frequently Asked Questions</strong></p><p>&nbsp;</p><p><strong>Why didn&rsquo;t the inhaler make a noise when I inhaled?</strong></p><p>The capsule may be stuck in the capsule chamber. If this happens, carefully loosen the capsule by tapping the base of the inhaler. Inhale the medicine again by repeating steps&nbsp;3a to 3d.</p><p>&nbsp;</p><p><strong>What should I do if there is powder left inside the capsule?</strong></p><p>You have not received enough of your medicine. Close the inhaler and repeat steps&nbsp;3a to 3d.</p><p>&nbsp;</p><p><strong>I coughed after inhaling &ndash; does this matter?</strong></p><p>This may happen. As long as the capsule is empty you have received enough of your medicine.</p><p>&nbsp;</p><p><strong>I felt small pieces of the capsule on my tongue &ndash; does this matter?</strong></p><p>This can happen. It is not harmful. The chances of the capsule breaking into small pieces will be increased if the capsule is pierced more than once.</p></td><td style="vertical-align:top"><p><strong>Cleaning the inhaler</strong></p><p>Wipe the mouthpiece inside and outside with a clean, dry, lint‑free cloth to remove any powder residue. Keep the inhaler dry. Never wash your inhaler with water.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Disposing of the inhaler after use</strong></p><p>Each inhaler should be disposed of after all capsules have been used. Ask your pharmacist how to dispose of medicines and inhalers that are no longer required.</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2020 by EMA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>